scientific reports

OPEN



The rat mammary gland undergoes dynamic transcriptomic and lipidomic modifications from prepuberty to adulthood

David Tovar-Parra¹, Alec McDermott¹, Melany N. Juarez¹, Jysiane Cardot¹, Mame Sokhna Sylla², Line Berthiaume², Géraldine Delbès¹, Martin Pelletier^{3,4}, Étienne Audet-Walsh^{2,5} & Isabelle Plante^{1⊠}

Mammary gland development is a complex process involving dynamic interaction between the epithelial and stromal components at different critical stages, particularly around puberty. While epithelial tissue changes are well-documented, stromal mechanisms are less understood. To address this gap, this study employed histology, lipidomic, and transcriptomic analyses to investigate molecular and cellular dynamics in the mammary gland during pre-puberty (Post Natal Day (PND21)), peri-puberty (PND46), and adulthood (PND90) in rats. The epithelial area was significantly smaller at PND21 than at PND46 and PND90, with a higher complexity at PND21 compared to PND46. Significant differences in adipocyte number and size were observed between PND21, PND46, and PND90. Transcriptomic analysis revealed that 1563 genes changed significantly between PND21 and PND46, with only 14 genes altered between PND46 and PND90. Enrichment analyses indicated dynamic regulation of pathways related to proliferation, differentiation, lipid metabolism, and immune responses. In lipidomic analysis, 29/43 and 7/43 fatty acids differed significantly between PND21 - PND46 and PND90, respectively. These results suggest that mammary gland development involves complex interactions between metabolic demands, hormonal regulation, and immune responses.

Keywords Mammary glands, Adipose tissue, Lipid metabolism, Adipocytes, Immunity

The development of the mammary gland spans from fetal stages to post-lactation involution and menopauseassociated involution¹. Morphologically, the mature secretory gland consists of branched tubuloalveolar structures composed of bilayered ramified ducts made mainly of luminal and myoepithelial cells. These structures end in secretory alveoli containing the lactocytes, specialized milk-secreting luminal cells². This epithelium is encompassed within a stromal tissue (also known as the fat pad), comprising predominantly adipocytes, immune cells, fibroblasts, endothelial cells, and extracellular matrix (ECM)³. The stroma serves a paracrine function pivotal in metabolism, fibroblast differentiation, immune responses, endothelial cell formation of the vascular network, and ECM dynamics^{4,5}.

From birth to adulthood, there is an elevation in sex-steroid hormones, including estrogen, progesterone, prolactin, androgens, and other hypothalamic-pituitary-ovarian hormones, collectively driving mammary gland transformation^{6,7}. These changes induce plasticity in mammary cells regulated by hormonal and molecular events affecting the machinery. Adipocytes contribute to mammary gland development and function by secreting various adipokines such as leptins, hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), adiponectin, and vascular endothelial growth factor (VEGF), that together regulate the epithelial tissue growth and differentiation⁸. Additionally, adipocytes act as a lipid depot that influences the glandular microenvironments and provides milk lipids^{9,10}. Lipids play crucial roles in regulating cell proliferation and

¹Institut National de la Recherche Scientifique INRS, Centre Armand-Frappier Santé Biotechnologie, Laval, Canada. ²Axe Endocrinologie-Néphrologie, Centre de recherche du CHU de Québec-Université Laval, Québec City, Canada. ³Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Québec City, Canada. ⁴Department of Microbiology-Infectious Diseases and Immunology, Faculty of Medicine, Université Laval, Québec City, Canada. ⁵Department of molecular medicine, Faculty of Medicine, Université Laval, Québec City, Canada. [⊠]email: isabelle.plante@inrs.ca differentiation, maintaining cellular membrane integrity, and acting as signals for modulating immune responses and protection against oxidative stress¹¹. During mammary gland development, lipid accumulation in adipocytes is essential as it provides a rapid source of fatty acids, supports tissue thermoregulation, and enhances de novo lipogenesis during epithelial tissue development¹². The presence of white adipocytes, composing white adipose tissue (WAT), is crucial for energy conservation, hormone secretion, and energy balance¹⁰, while brown adipocytes contribute to the formation of brown adipose tissue (BAT), playing a role in the thermal regulation of mammary tissue¹³.

During mammary gland development, integration between the stroma and the immune cell compartment also dynamically alters mammary structure and function. Although less studied, in animal models, macrophages, eosinophils, mast cells, and lymphocytes have been associated with regulating branching morphogenesis, promoting terminal bud formation (TEBs), and post-lactation regression³.

These processes are influenced by transcriptional regulations contributing to mammary tissue cell plasticity. Previous studies have utilized approaches like flow cytometry to identify cellular markers and better understand the role of different cellular lineages in mammary tissue differentiation and development^{7,14}. Advanced techniques such as single-cell RNA sequencing have expanded our understanding of transcriptional profiles of individual cells, including adipocytes and other stromal and epithelial populations comprising the gland^{15–17}. Despite these advances in understanding the processes involved in mammary gland development, there remains a lack of comprehension regarding the role of stromal tissue in this process and how the physiological functions of the tissue depend on interactions between its cellular and molecular components¹⁸. Doria et al. reported that 68 genes involved in lipid metabolism differed when the mammary epithelial cells were differentiated compared with undifferentiated or proliferative cells, which resulted in increased levels of C16:1 (Palmitelaidic acid), C18:1 (Oleic acid), C20:3 (Dihomo- γ -linolenic acid), and C20:4 (Arachidonic acid) fatty acids (FAs) and more phospholipids (PLs) in these cells¹⁹. These studies indicated a clear relation between the transcriptional regulation and the lipid compositions of the mammary gland, which could affect its development.

In this study, we utilized whole mammary tissue to compare morphological and physiological parameters from pre-puberty to adulthood, identifying differences in gene expression profiles using RNA sequencing. Furthermore, we evaluated changes in fatty acid composition using lipidomics, exploring how lipid dynamics in adipocytes impact mammary gland development and function. This integration of lipidomic and transcriptomic analyses provides a deeper understanding of the underlying mechanisms regulating mammary gland development and function, emphasizing the crucial role of adipocytes, lipids, and immune cells in these complex biological processes.

Results

Mammary epithelial and stroma undergo morphological changes across the development

To first study the development of the rat mammary gland from pre-puberty to adulthood, a total of 19 rats were used for the study: 7 rats in the pre-pubertal group (Postnatal day (PND21)), 7 in the peri-pubertal group (PND46), and 5 in the adult group (PND90) (Fig. 1A). As expected, significant differences were found in body and mammary gland weights between the PND21 and PND46 groups, and the PND21 and PND90 groups (Fig. 1B), resulting in mammary gland over body weight ratios that were smaller in PND46 and PND90 animals compared with PDN21 (Fig. 1B).

We then confirmed that those stages were reflective of major changes in the epithelium using whole-mount. As expected, the total epithelial area was found to increase during development, from an average of 0.6 cm² for PND21 rats, to 2.6 cm² for PND46 rats and 7.2 cm² for PND90 rats, with significant differences among all groups (Fig. 1C–D). While the epithelial area increased, the complexity of the epithelial tissue, as measured using the number of intersections per cm², was found to be greater in PND21 rats compared to PND46 and PND90 rats (Fig. 1D). Altogether, these results show that while the epithelial area is increasing from PND21 to PND90, the number of ramifications is maximal at PND21 and remains stable between PND46 and PND90.

Transcriptional dynamics and differential expression gene analysis in mammary development

To understand the composition of mammary tissue and gene expression dynamics, RNA-seq profiles were generated from mammary glands across the three developmental stages (PND21, PND46, and PND90). After quality control, a principal component analysis (PCA) was conducted to visualize the variations in gene distribution across the groups, revealing a clear separation between the PND21 group and the PND46 and PND90 groups (Fig. 2A). While pre-puberty glands were distinct, mature/adult glands exhibited a similar transcriptional profile. During the transition from PND21 to PND46, 1,582 genes were differentially expressed, as identified using DESeq2 (662 downregulated and 924 upregulated) (Fig. 2B). In contrast, only 14 genes were significantly modulated during the transition from PND46 to PND90 (1 downregulated and 13 upregulated) (Fig. 2C).

Gene Ontology (GO) analyses of genes differentially expressed during the transition from PND21 to PND46 revealed associations with biological processes such as fatty acid metabolism, adaptive immune response, regulation of cell-cell adhesion, and T-cell activation (Fig. 2D). Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses indicated that upregulated genes were enriched for chemokine signaling pathways (map04062 $^{20-22}$) (Fig. S1), cytokine-cytokine receptor interaction, the transcriptional factor NF- κ B, cell adhesion molecules, natural killer cell-mediated cytotoxicity, Th1 and Th2 differentiation, and B cell receptors (map04060 and map04662 $^{20-22}$) (Fig. S2 A-B). To validate these RNA-seq results, we performed qPCR of specific genes. Genes associated with the immune response, which were increased over time in RNA-seq analyses (Fig. 2B), including *Tnfrsf11a* (TNF receptor superfamily member 11a), *Irf7* (interferon regulatory



Fig. 1. Morphologic characteristics of mammary gland sampled from rats during pre-puberty (PND21), peri-puberty (PND46), and adulthood (PND90). (**A**) Representative diagram of mammary gland sampling. (**B**) Average body weight, mammary gland weight, and mammary gland weight normalized to total rat weight per group. (**C**) Left: representative images of whole mount for each group (scale bar 1 cm). Right: graphic representation of the skeletonized epithelium of the mammary gland obtained from those images using ImageJ. (**D**) Average epithelial area and epithelial complexity) for each group, obtained using whole-mount images. Graphs represent the average of the group with SD (*p < 0.05, **p < 0.01, ***p < 0.001).

.....

factor 7), *Traf1* (TNF receptor associated factor 1), and *Cd3e* (CD3 epsilon subunit of T-cell receptor complex), showed increased expression during the transition from PND21 to PND46 and PND90 by qPCR (Fig. S3A). These results suggest increased transcriptional activation of genes/gene networks implicated in the activity of the immune compartment.

Conversely, downregulated genes were enriched in pathways related to fatty acid biosynthesis, the TCA cycle, fatty acid elongation, pyruvate metabolism, AMPK signaling, and Peroxisome proliferator-activated receptor (PPAR) signaling (map04923 and map03320 $^{20-22}$) (Fig. S4 A-B). The AMPK signaling pathway is the guardian of metabolic health, playing a pivotal role in regulating fatty acid beta-oxidation and lipogenesis in cells, while PPAR is crucial for adipocyte differentiation²³. Again, we performed qPCR validation of key target genes, including *Fabp4* (fatty acid binding protein 4), *Pparg* (peroxisome proliferator-activated receptor *y*), and *Scd* (stearoyl-CoA desaturase 1). As observed in RNA-seq (Fig. 2B), all three genes were significantly lower in PND46 and PND90 compared to PND21 (Fig. S3B). These results suggest that after pre-puberty, an important metabolic reprogramming occurs, notably affecting lipid metabolism at the transcriptional level.



Fig. 2. Identification of differentially expressed genes using RNA-sequencing analysis between PND21 to PND46, and PND90. (**A**) Principal component analysis showing the normal distribution of the groups PND21, PND46, and PND90. (**B**) Volcano plot illustrating the significantly upregulated (red), downregulated (blue), and not significant (not sig (grey)) genes in the transition between PND21 and PND46 of rat's mammary gland (p-adj < 0.05, Log₂FC 1.5, *n* = 4). (**C**) Volcano plot illustrating the significantly upregulated and downregulated genes in the transition between PND46 and PND90 of rat's mammary gland (p-adj < 0.05, Log₂FC \geq 1.5, *n* = 4). (**C**) Gene Ontology enrichment analysis of biological processes for upregulated and downregulated genes during the transition between PND21 and PND46.

Relative gene expression patterns differ between developmental stages

To further understand the processes involved in mammary gland development, k-means clustering analyses were performed. Four clusters were defined based on the relative expression levels of genes in the samples, with most transcriptional signatures differentiating PND21 specifically from PND46 and PND90, which exhibited a similar profile (Fig. 3A). This result aligns with DESeq2 analyses (Fig. 2), with an overlap observed in the transcriptional profiles of the PND46 and PND90 stages. Interestingly, genes from clusters 1 and 2 generally showed a higher expression at PND21 compared with PND46 and PND90, while genes from clusters 3 and 4 showed an opposite pattern.

Pathway enrichment analyses of the clusters revealed associations with mammary gland development terms such as cellular and differentiation dynamics (Cluster 1). Genes highly expressed in cluster 1 were mainly enriched in terms of signaling pathways related to extracellular matrix reorganization, response to growth factors, cellular homeostasis, and vascular development, among others (Fig. 3B). These gene signatures are consistent with the reorganization of the gland, a process that requires epithelial tissue growth, formation and elongation of new branching through the formation of TEBs²⁴.

Cluster 2, related to metabolic and proliferative regulation, involved processes such as cell cycle regulation, oxidative phosphorylation, the tricarboxylic acid cycle (TCA cycle), acyl-CoA metabolic process, and pyruvate metabolism, among other cellular metabolic processes (Fig. 3C). Changes in metabolic gene expression during



Fig. 3. Hierarchical cluster analysis by K-Means from the PND21, PND46, and PND90 groups. (**A**). Heatmap showing k-mean gene expression. Rows represent genes clustered using K-means clustering, and columns represent samples (n=4) from PND21, PND46, and PND90. Metascape enrichment network visualizations of the most common genes (**B**) in cluster 1 related to cellular growth and differentiation dynamics, (**C**) in cluster 2 related to metabolic and proliferative regulation, (**D**) in cluster 3 related to hormonal regulation and stress response, and (**E**) in cluster 4 related to immune response and cellular signaling dynamics, in the mammary gland tissue from PND21, PND46, and PND90 rats. Black arrows point to the specific pathways in each cluster that relate to mammary gland development.

development suggest an important metabolic reprogramming throughout the mammary gland evolution, notably between pre-puberty and peri-puberty/adulthood.

Cluster 3, associated with hormonal regulation and stress response, involves processes such as cell junction organization, cell morphogenesis, response to steroid hormones, reproductive structure development, and regulation of epithelial cell proliferation, supporting processes like epithelial-mesenchymal transition and proliferation of luminal and myoepithelial cells (Fig. 3D).

Finally, cluster 4 is associated with immune response and cellular signaling dynamics, including positive regulation of immune response, cytokine production, programmed cell death, leukocyte activation, and JAK-STAT signaling pathways, among others (Fig. S1). This calls our attention to the known importance of immune cells in the remodeling of mammary gland development²⁴. Given our interest in the role of the stromal compartment, we decided to focus on clusters 2 and 4, as they are more closely related to functions generally attributed to the stroma, such as lipid metabolism and immune functions.

Metabolic and proliferative regulation across developmental stages

The relative gene expression data showing that cluster 2 was associated with metabolic reprogramming and with differentially expressed gene analyses suggested that metabolic pathways were affected during the PND21 to PND46 transition. An overlap analysis was thus conducted to uncover the molecular mechanisms related to metabolism and proliferative processes. This analysis compared genes in cluster 2 with genes upregulated and downregulated in the differentially expressed gene analysis. Specifically, only downregulated genes identified in differential expression analysis were part of cluster 2, with 197 genes, while no upregulated genes overlapped with this cluster (Fig. 4A). These results further emphasized that an important metabolic reprogramming at the transcriptional level during the transition from pre-puberty to peri-puberty. Downregulated genes included some related to *de novo* synthesis of fatty acids, such as Acetyl-CoA carboxylase-a (*Acaca*), Diacylglycerol O-acyltransferase 1 (*Dgat1*), Monoacylglycerol O-acyltransferase 2 (*Mogat2*), Perilipin 1 (*Plin1*), and Fatty acid desaturase 3 (*Fads3*) (Fig. S4A). Enrichment pathway analysis confirmed this relationship between downregulated genes and lipid metabolism, with enrichment of processes like acyl-CoA, adipogenesis, lipid droplet organization, and long-chain fatty acid metabolic processes that were downregulated (Fig. 3B).

A Gene Set Enrichment Analysis (GSEA) was then performed using normalized sequencing data to compare PND21 to PND46 and PND46 to PND90 rats. GSEA confirmed a significant decrease in adipogenesis and fatty acid metabolism gene sets across all stages, with normalized enrichment scores (NES) of 3.19 to 2.64 and 2.84 to 2.10 in the transition from PND21 to PND46 and from PND46 to PND90, respectively (Fig. 3C, D). Among the downregulated genes related to adipogenesis, we found *Ppary*, Leptin (*Lep*), Adiponectin (*Adipoq*), CCAAT/enhancer-binding protein-a (*Cebpa*), and *Fabp4*, and genes involved in fatty acid synthesis like Fatty acid synthase (*Fasn*), *Scd*, *Fabp4*, *Acaca*, and Glycerol-3-phosphate dehydrogenase 1 (*Gpd1*) (Fig. S4B), and the expression level were reduced in PND46 and PND90 compared to PND21 as validated by qPCR for specific genes (Fig. S3).

Together, these data suggest that during these developmental transitions, especially from pre-puberty to peri-puberty (PND21 to PND46), the rapid division of epithelial cells leading to the growth and elongation of epithelial tissue requires significant energy, ECM reorganization, stromal tissue, and materials like lipids, which form various cellular membranes. To further support these findings, the concentrations of fatty acids in mammary tissue were determined using gas chromatography analysis. A significant decrease in total fatty acid concentration was observed during the transition from PND21 to PND46, while no significant differences were observed during the transition from PND46 to PND90 (Fig. 3E; Table 1).

Lipid expression patterns across developmental stages

Given the changes in the transcriptional profiles during mammary gland development, we hypothesized that lipid metabolism might play a central role in mammary gland development, especially during the transition from pre-puberty to peri-puberty (PND21 to PND46). To investigate whether the differential expression of lipid metabolism genes was reflected in differential lipid abundance, we performed a lipidomic analysis and quantitatively compared the lipid profiles between the three stages of development. In our study, 43 fatty acids were quantified and classified into 15 groups based on their characteristics (Table 1). Of these, 29/43 fatty acids and 10/15 groups differed significantly between PND21 and PND46, while only 7/43 fatty acids and 0/15 groups showed differences between PND46 and PND90. Together with transcriptional analyses (Figs. 2, 3 and 4), these results highlight the profound changes in lipid metabolism that notably occur between pre-puberty and peripuberty.

To visualize the distribution of fatty acids, we conducted PCA and found that short and medium-chain saturated fatty acids were more concentrated in the PND21 group compared to the PND46 and PND90 groups, indicating a clear separation between the lipid profile in PND21 compared to PND46 and PND90 (Fig. 5A). PND46 and PND90 exhibited a similar lipid profile (Fig. 5A). Heatmap clustering, considering fatty acid concentrations, confirmed the presence of Lipid-cluster 2 and Lipid-cluster 3, which are associated with higher concentrations of short-chain and medium-chain saturated lipids, respectively in the PND21 stage compared to PND46 and PND90 (Fig. 5B). To understand the fatty acid distribution, we performed a correlation analysis among fatty acids for each stage and compared the results between the groups (Fig. 5C). We observed an increase in positive correlation among saturated and unsaturated medium- and long-chain fatty acids during the transition from PND21 to PND46. Conversely, during the transition from PND46 to PND90, there was a strong positive correlation among fatty acids in the PND90 stage, indicating co-regulation of fatty acids and the establishment of metabolic patterns during mammary gland development in adult stages (Fig. 5C). However, we found that some lipids in PND21, such as C16:0 DMA (1,1-dimethoxyhexadecane), in PND46, such as C16:0



Fig. 4. Identification of lipid metabolic reprogramming pathways and adipogenesis in the transition between PND21 and PND46 via transcriptome analysis. (**A**) Venn diagram for overlapping significant genes downregulated and upregulated and cluster 2 during the transition between PND21 and PND46. (**B**) Enrichment pathway analysis using overlapping genes. (**C**) and (**D**) Gene Set Enrichment Analysis (GSEA) plots for biological pathways enriched in the transition between PND21 to PND46 and PND90. Hallmarks gene sets are shown for (**C**) adipogenesis and (**D**) fatty acid metabolism during the transition between PND21 to PND46 and PND46 to PND90. NES; Normalized enrichment score. The red color indicates higher expression in heatmaps, and the blue color indicates lower expression. (**E**) Graphic representation of total fatty acid across developmental stages. Error bars represent SD, (***p < 0.001).

DMA, 13c16c19c-22:3 n3 (docosadienoic acid), and in PND90, such as C8:0 (caprylic acid), C16:0 DMA, and 9t12c-18:2 n6 (linoleic acid (trans, cis isomer)) exhibited negative correlations with the other fatty acids (Fig. 5C).

Various biological processes, such as cell growth, proliferation, and development, require the formation of new cellular components with energy and lipid demands²⁵. Our results indicate that during the transition from PND21 to PND46, different groups of fatty acids significantly decrease in concentration within the tissue, including saturated fatty acids, total cis fatty acids, total omega-6 and omega-3, and the ratio of omega-3 to omega-6 (Fig. 5D). These fatty acids are involved in cell membrane structure, energy production, membrane

Image: space s	Fatty Acids	Carboxyl nomenclature	PND21	PND46	PND90
Capric acid080015.007.0Capric acid1000200730.030.0Capric acid120030.08.08.0Myritacic acid14000.00.00.00.0Dettade-moic acidC16.00.000.000.000.001.1.DrenthoyheadeaneC16.00.000.000.000.00Pandacencic acid0.1510.000.000.000.00Dettade-moic acid0.161.00.000.000.000.00Dettadeancic acid0.161.00.000.000.000.00Detopadacancic acid0.171.00.000.000.000.00Detopadacanci acid0.171.00.000.000.000.00Detopadacanci acid (ria nisome?)C171.070.000.000.00Paradacenci acid (ria nisome?)C171.070.000.000.00Detopadacanci acid (ria nisome?)C171.070.000.000.00Starci acid10.010.010.010.000.00Detocacid acid (ria nisome?)C171.070.000.000.00Consca acid10.010.010.010.000.00Detocacid10.010.010.010.010.01Consca acid10.010.010.010.010.01Consca acid10.0110.010.010.010.01Consca acid10.0110.010.010.010.01Consc			Mean (m	ng FA/g)	
Capica sid1000200730.72Lauric acid120043.18.223.26Mysita cad14.604.518.201.506.81Mysita cadC1500.760.510.870.77Pendacanoic acidC150 DMA0.300.870.77Pendacanoic acid (trans isomer)C151 In 510.140.800.14Palmite acid0.6000.770.8370.721.27Palmite acid0.940.170.900.140.121.28Palmite acid0.940.170.900.120.211.21Mantokic acid0.710 isobranched0.170.700.210.21Palmite acid0.710 isobranched0.710.700.210.21Magrafic acidC17.0170.700.710.700.71Palmite acid (trans isomer)C17.170.730.730.730.73Staric acid116.18.170.730.740.740.74Parto-accinic acid116.18.170.740.740.740.74Caroig acid (trans isomer)116.18.170.230.140.110.750.75Vacenci acid116.18.170.740.740.740.740.74Caroig acid (trans isomer)116.18.170.740.740.740.74Caroig acid (trans isomer)116.18.170.740.740.740.74Caroig acid (trans isomer)116.18.170.750.75 <td>Caprylic acid</td> <td>08:00</td> <td>1.51</td> <td>0.2</td> <td>0.07</td>	Caprylic acid	08:00	1.51	0.2	0.07
LamIzon4.3.9.2.9.2.Myritolic acid140049.2.1.3.66.8.Myritolic acid96-14.1.5.0.700.5.0.8.Pendacenoic acid (trans isomer)C150 DMA0.030.020.14.Pathadecenoic acid (trans isomer)C151 In510.140.020.14.Palmitelaidic acid9.16.1.070.090.040.12Palmitelaidic acid9.16.1.070.090.040.12Palmitelaidic acid0.17.0 isomanched1.100.120.12Palmitelaidic acid2.16.1.070.270.210.25Palmitelaidic acid0.11.0 isomanched0.11.0 isomanched0.11.0 isomanched0.11.0 isomanchedPalmatelaidic acid (trans isomer)C17.1.070.270.210.21Patradecenoic acid (trans isomer)C17.1.070.270.210.21Patradecenoic acid (trans isomer)C17.1.070.410.400.41Olicia acid0.12.1.00.110.110.120.12Vacenic acid11.81.070.410.410.410.41Olicia acid0.12.1.00.120.120.120.12Indicia acid (trans.cisiomer)11.2.18.1.00.230.210.11Indicia acid (trans.cisiomer)0.12.1.00.120.120.12Indicia acid (trans.cisiomer)0.12.1.00.120.120.12Indicia acid (trans.cisiomer)0.12.1.00.120.120.12Indicia acid (t	Capric acid	10:00	20.07	3	0.72
Myristic add 1400 49.2 13.26 6.48 Myristic add 9-14.1 n.5 0.76 0.51 0.38 Partadacanoic acid C15.0 0.49 0.77 0.77 1.1 - Dimethoxyhexadecane C16.0 DMA 0.04 0.03 0.08 0.07 Partitadecanoic acid (trans isomer) C15.1 nsft 0.14 0.08 0.04 0.03 Isoheptadecanoic acid 9-16.1 n.7 0.90 0.04 0.03 1.02 Palmitoleic acid 9-16.1 n.7 0.20 0.21 0.26 Margaric acid C17.0 isobranched 0.11 0.07 0.21 0.26 Haptadecenoic acid (trans isomer) C17.1 n.7 0.27 0.21 0.26 Li Dymethoxycradecane C18.1 DMA 0.41 0.41 0.35 Stearic acid 11c.18.1 n.7 0.45 6.33 8.39 Vaccenic acid (trans isomer) 912.1.82.n6 0.22 0.21 0.17 Lindica cid 1.62.18.1 n.9 0.23 0.14 0.35 Vaccenic acid (trans. cis isomer) 912.1.82.n6 0.22 0.21 0.17 Lindica cid 1.62.18.1 n.9 0.22 0.21 0.17 Conjagged linoloic acid (trans. cis isomer) <td>Lauric acid</td> <td>12:00</td> <td>43.1</td> <td>8.92</td> <td>2.6</td>	Lauric acid	12:00	43.1	8.92	2.6
Myrstoleic acid9.4-141 n50.760.510.87Pentalecanoic acidC150 DMA0.060.070.87Pentalecanoic acid (trans isomer)C151 Dsf0.140.080.01Palmitchaific acid1600133.7169.7272.51Palmitchaific acid9.161 D.70.090.400.31Isohpatecanoic acid9.161 D.70.090.400.32Palmitchaific acid9.161 D.70.090.520.22Palmitchaific acid9.161 D.70.070.120.21Palmitchaific acid9.161 D.70.200.210.26Myrapric acidC17.1 D.70.270.210.26Lybadeconoic acid (trans isomer)C17.1 D.70.270.210.21Lybtadeconoic acid (cis isomer)C17.1 D.70.270.410.41Olcic acid9181 D.90.14110.4176.68Stearc acid9181 D.90.14110.4176.68Olcic acid9181 D.90.14110.4176.68Vaccenic acid110-181 D.70.1410.110.10Olcic acid110-182 D.60.220.210.17Linolet acid (trans.ci siomer)9.12-182 D.60.330.340.34Oringized Inolet acid (trans.ci siomer)9.12-182 D.60.350.1410.12Linolet acid0.240.210.170.140.150.16Conjagaed Inolet acid (trans.ci siomer)9.12-182 D.60.350.140.15 </td <td>Myristic acid</td> <td>14:00</td> <td>49.22</td> <td>13.26</td> <td>6.48</td>	Myristic acid	14:00	49.22	13.26	6.48
Pentadecanoic acidC1500.960.570.671.1-DimethoxyheradecameC160 DMA0.030.080.07Pentadeconic acid (trans isomer)C151 Is710.140.080.04Palmitis acid9:161 n70.090.040.03Ioneptadecanoi acidC17.0 isobbranched0.110.070.22Palmitoleic acid9:-161 n70.960.590.72Palmitoleic acidSe:-161 n71.070.260.21Palmitoleic acidC17.0 n70.960.590.72Lybradecenoic acid (trans isomer)C17.1 n70.530.450.48Petradecenoic acid (cisomer)C17.1 n70.530.451.21.3Trans-vaccenic acid110-181 n70.410.410.36Oleic acid9:-181 n0104.167.6088.49Vaccenic acid110-181 n70.220.210.17Conjugatel linoleic acid (trans. isomer)912-182 n60.220.210.17Conjugatel linoleic acid (TAA)6:92-183 n61.8271.324147.33Arachide acid110-20.11.720.610.110.12Conjugatel linoleic acid (TAA)6:92-183 n61.8271.324147.33Arachide acid110-20.11.720.610.110.11Conjugatel linoleic acid (TAA)6:92-183 n61.8271.3241.72Arachide acid0.200.210.210.210.21Conjugatel linoleic acid (TAA)6:92-183 n	Myristoleic acid	9c-14:1 n5	0.76	0.51	0.38
1.1-Dimethoxyheradecane C160 DMA 0.03 0.68 0.07 Pentadeconoic add (trans isomer) C151 n51 0.14 0.80 0.14 Palmitelaidic acid 1600 13.37 69.72 72.51 Palmitelaidic acid 91-161 n7 0.09 0.04 0.03 Isoheptadecanoic acid C17.01 bobranched 0.11 0.07 0.12 Palmitoleia caid Section 12.07 11.44 12.67 Margaric acid C17.0 0.96 0.59 0.72 Heptadecenoic acid (trans isomer) C17.1 n7 0.53 0.45 0.48 Staaric acid 1800 17.58 10.78 10.78 13.67 Oleic acid 9c.181 n9 101.16 7.08 3.49 14.04 Vaccenci acid 11c-181 n7 0.59 6.35 8.3 Peroselinic acid 11c-181 n7 0.21 0.14 0.11 0.01 0.11 10.10 0.11 10.10 0.11 10.10 0.11 10.10 0.11 10.10 0.11 11.1 11.0 0.11 11.1 1	Pentadecanoic acid	C15:0	0.96	0.57	0.67
Pentadecenoic acid (trans isomer)C15:1 n5t0.140.080.14Palmitclack16:0013:7.067:272.5.1Palmitclack acid9:1-61 n70.090.040.03Isoheptadecanoic acidC17:0 isobranched0.110.070.12Palmitclack acid9:1-61 n712.0711.8412.07Margaric acidC17:0 n00.960.270.210.26Input acidC17:1 n7t0.270.210.261.1-DimethosyottadecaneC18:1 DMA0.110.00.16Agraric acid18:0017.5810.7812.13Trans-accenic acid (cis isomer)C17:1 n7c0.410.410.36Oleic acid9:18:1 n70.410.400.36Oleic acid11:18:1 n70.410.410.36Oleic acid11:2:18:1 n50.330.140.19Conjugatel linoleic acid (trans. cis isomer)11:2:18:1 n50.320.14Conjugatel linoleic acid (TAA)ALS 02:12:18:3 n6188.00.70Arachidic acidC220.210.70.11Conjugatel linoleic acid (DAA)ALS 02:12:18:3 n61.800.81Arachidic acidC220.210.270.210.27Arachidic acidC220.210.170.210.21Arachidic acidC220.210.270.210.27Arachidic acidC220.210.210.210.21Arachidic acidC220.2	1.1-Dimethoxyhexadecane	C16:0 DMA	0.03	0.08	0.07
Palmitic acid16:00133.7169.7272.51Palmitalacia caid9:161:170.090.040.03Lobeptadecanoic acidC170 isobranched0.110.070.12Palmitolici acid9c-161:1712.0711.8412.67Margaric acidC17.00.270.210.26Heptadecenoic acid (trams isomer)C17.1 n7r0.370.210.26L1-DimethoxyoctadecaneC181:DMA0.1100Heptadecenoic acid (cis isomer)C17.1 n7r0.530.450.48Stearic acid116:18:1n70.410.410.36Cleic acid9c-181:n9104.167.68884.49Vaccenic acid11c-181:n70.230.140.19Conjugated linoleic acid (trans. cis isomer)912c-182:n60.220.210.17Linoleic acidLA Sel22-182:n61.82.711.34.7147.53Arachidi acid20000.210.190.210.190.21Gamma-linolenic acid (GLA)A Sel21c-183:n51.128.108.10Condoic acid11c-20:1n91.120.00.110.10Linoleic acid11c-20:1n91.120.00.110.10Linoleic acid (GLA)A Sel21c-183:n51.320.100.11Linoleic acid (GLA)A Sel21c-184:n30.310.010.11Linoleic acid (GLA)A Sel21c-184:n30.310.010.21Condoic acid11620.00.330.3	Pentadecenoic acid (trans isomer)	C15:1 n5t	0.14	0.08	0.14
Palmitelaidic acid9:161 n70.090.040.03Isoheptadecamoic acidC170 leobranched0.110.070.12Palmitoleic acidSe-161 n712.0711.4012.67Margaric acidC170 n0.960.590.72Iteptadecenoic acid (trans isomer)C17.1 n7.0.530.450.68Petpatacenoic acid (cis isomer)C17.1 n7.0.530.450.16Searic acid18.0017.5810.7813.68Staric acid11-18.1 n70.410.400.36Oleka acid9-18.1 n9104.1670.688.49Vaccenic acid (cis isomer)11.61.81.178.596.358.30Oleka acid9-18.1 n910.4170.688.49Vaccenic acid11.61.81.078.596.378.37Vaccenic acid9.12.18.150.220.210.17Conjugatal linolici acid (trans. cis isomer)11.28.17.6018.8213.40Anachidic acid20000.210.100.11Anachidi acid20000.210.100.11Anama-linolenic acid (GLA)ALA 94C215-18.3 n311.728.10Apha-linolenic acid (LA)ALA 94C215-18.3 n311.728.10Apha-linolenic acid6.99C1215-18.410.310.100.21Itabel acid11.62.01.1911.200.100.1010.20Itabel acid11.62.01.191.200.100.100.10Itabel acid11.62.02.16<	Palmitic acid	16:00	133.71	69.72	72.51
Isoheptadecanoic acid C17.0 isobranched 0.11 0.07 0.12 Palmitolice acid 9c-161 n7 12.07 11.84 12.07 Margaric acid C17.0 0.96 0.59 0.72 Heptadecenoic acid (trans isomer) C17.1 n7t 0.27 0.21 0.26 1.1-Dimethoxyoctadecane C18.1 DMA 0.11 0 0 Heptadecenoic acid (cis isomer) C17.1 n7c 0.53 0.45 0.48 Stearic acid 18.00 1.758 10.63 8.49 Vaccenic acid 11-18.1 n7 8.59 6.53 8.3 Patcoselinic acid 12.18.1 n5 0.23 0.14 0.19 Conjugated linoleic acid (trans. cis isomer) 912c-18.2 n6 0.22 0.2 0.17 Candidac acid 2.00 0.11 0.0 0 0 Candidac acid 1.49 v12c-18.2 n6 1.88 0.74 0.75 Arachidic acid 1.49 v12c-18.2 n6 1.88 0.74 0.7 Alpha-linolenic acid (GLA) <td< td=""><td>Palmitelaidic acid</td><td>9t-16:1 n7</td><td>0.09</td><td>0.04</td><td>0.03</td></td<>	Palmitelaidic acid	9t-16:1 n7	0.09	0.04	0.03
Palmitoleic acid 9c-161 n7 12.07 11.84 12.67 Margaric acid C17:0 0.96 0.99 0.72 Heptadecenoic acid (trans isomer) C17:1 n7t 0.21 0.26 1.1-Dimethoxyoctadecane C18:1 DMA 0.11 0 0 Heptadecenoic acid (cis isomer) C17:1 n7c 0.53 0.45 0.48 Staaric acid 11t-18:1 n7 0.41 0.41 0.36 Oleic acid 9c-18:1 n9 104.16 76.08 84.49 Vaccenic acid 11c-18:1 n7 0.41 0.19 0.19 Conjugated linoleic acid (trans. cis isomer) 912c-18:2 n6 0.22 0.21 0.17 Linoleic acid 1.49 vc12c-18:2 n6 0.82 0.21 0.19 0.21 Gamma-linolenic acid (ALA) 66:42c-18:3 n6 1.98 0.74 0.72 Alpha-linolenic acid (ALA) ALA 9c12c15c-18:4 n3 0.31 0.01 0 Gondoic acid 11c-14c-20:2 n6 3.05 1.01 1 1 Eicosaentic	Isoheptadecanoic acid	C17:0 isobranched	0.11	0.07	0.12
Margaric acid C17.0 0.96 0.59 0.72 Heptadecenoic acid (trans isomer) C17.1 n7t 0.27 0.21 0.26 1.1-Dimethoxyotadecane C17.1 n7t 0.53 0.45 0.48 Heptadecenoic acid (cis isomer) C17.1 n7c 0.53 0.45 0.48 Stearic acid 18:00 17.58 10.78 12.13 Trans-vaccenic acid 91:18:1 n7 0.41 0.41 0.41 0.36 Oleic acid 11c-18:1 n7 8.59 6.35 8.3 Petroselinic acid 11c-18:1 n7 8.59 6.35 8.3 Petroselinic acid (GLA) 13c-18:2 n6 168:27 12.347 147:53 Arachidic acid (GLA) 69:64:12:-18:3 n6 1.98 0.74 0.72 Alpha-linolenic acid (ALA) 69:42:12:15:-18:4 n6 1.98 0.74 0.73 Alpha-linolenic acid 112 0 0 0 11 Eicosatienoic acid 11:2 0.71 0.66 13:6 13:6 13:6	Palmitoleic acid	9c-16:1 n7	12.07	11.84	12.67
Heptadecenoic acid (trans isomer) C17:1 n7t 0.27 0.21 0.26 1.1-Dimethoxyoctadecame C18:1 DMA 0.11 0 0 Heptadecenoic acid (cis isomer) C17:1 n7c 0.53 0.45 0.48 Stearic acid 18:00 17.58 10.78 12.13 Tams-vaccenic acid 11t-18:1 n7 0.41 0.41 0.36 Oleic acid 9c-18:1 n9 10.416 76.08 84.49 Vaccenic acid 11c-18:1 n5 0.23 0.14 0.19 Conjugatel linoleic acid (trans. cis isomer) 912c-18:2 n6 0.22 0.21 0.17 Linoleic acid (GLA) 65:012c-18:3 n6 1.98 0.74 0.7 Arachidic acid 20:00 0.21 0.19 0.21 Gondoic acid 11c-20:1 n9 1.12 0.77 0.6 Stearionic acid 11c-20:1 n9 1.12 0.77 0.6 Stearionic acid 11c-20:1 n9 1.12 0.77 0.6 Stearionic acid 11c-20:1 n9 1.2 0.7 0.6 Stearionic acid 22:00 0	Margaric acid	C17:0	0.96	0.59	0.72
1.1-Dimethoxyoctadecane C18:1 DMA 0.11 0 0 Heptadecenoic acid (cis isomer) C17:1 n7c 0.53 0.45 0.48 Stearic acid 18:00 17.58 10.75 10.758 10.758 10.75 10.758 10.75	Heptadecenoic acid (trans isomer)	C17:1 n7t	0.27	0.21	0.26
Heptadecenoic acid (cis isomer) C17:1 n7c 0.33 0.45 0.48 Stearic acid 18:00 17.58 10.78 12.13 Trans-vaccenic acid 91-18:1 n7 0.41 0.41 0.36 Olcic acid 92-18:1 n9 10.16 76.08 84.49 Vaccenic acid 11c-18:1 n7 8.59 6.35 8.3 Petroselinic acid 13c-18:1 n5 0.23 0.14 0.19 Conjugated linoleic acid (trans. cis isomer) 912c-182 n6 0.22 0.21 0.17 Gamma-linolenic acid (GLA) 6.942c-18:2 n6 1.98 0.74 0.7 Alpha-linolenic acid (GLA) 6.942c-18:2 n6 1.98 0.74 0.7 Alpha-linolenic acid (GLA) 8.200-11 n12 0 0 0 0 11-Eicosenic acid 11c-201 n9 1.12 0.77 0.6 Stearidonic acid 626-12c-18:4 n3 0.31 0.01 0 Li-Eicosadienoic acid 11c-20:1 n9 1.12 0.77 0.6 Stearidonic acid 11c-20:1 n9 0.23 0.2 0.22 0.22 <tr< td=""><td>1.1-Dimethoxyoctadecane</td><td>C18:1 DMA</td><td>0.11</td><td>0</td><td>0</td></tr<>	1.1-Dimethoxyoctadecane	C18:1 DMA	0.11	0	0
Stearic acid 18.00 17.58 10.78 12.13 Trans-vaccenic acid 111-18:1 n7 0.41 0.41 0.36 Oleic acid 9c-18:1 n9 104.16 76.08 84.49 Vaccenic acid 11c-18:1 n7 0.23 0.14 0.19 Conjugated linoleic acid (trans. cis isomer) 9112-18:2 n6 0.22 0.21 0.17 Linoleic acid LA 9c12c-18:2 n6 0.22 0.21 0.17 Gamma-linolenic acid (GLA) 6c9c12c-18:3 n6 1.98 0.74 0.7 Arachidic acid 2000 0 0 0 11-1 I-Eicosonic acid 11c-20:1 n9 1.12 0.7 0.6 Staridonic acid 11c-120:1 n9 1.12 0.7 0.6 Staridonic acid 11c-120:1 n9 1.12 0.7 0.6 Staridonic acid 11c-14c-20:2 n6 3.05 1.01 1 Eicosadienoic acid 11c-14c-20:2 n6 3.05 1.01 1 Eicosadienoic acid 121.6c-22:1 n6 0.14 0.05 0.07 Arachidonic acid DAS Start124c	Heptadecenoic acid (cis isomer)	C17:1 n7c	0.53	0.45	0.48
Trans-vaccenic acid 111-18:1 n7 0.41 0.41 0.36 Oleic acid 9c-18:1 n9 104.16 76.08 84.49 Vaccenic acid 11c-18:1 n7 8.59 6.35 8.3 Petroselinic acid 13c-18:1 n5 0.23 0.14 0.19 Conjugated linoleic acid (trans. cis isomer) 9112c-18:2 n6 0.22 0.21 0.17 Linoleic acid LA 9c12c-18:2 n6 168:27 123.47 147.53 Arachidic acid (GLA) ALA 9c12c-18:3 n3 11.72 8.01 9.81 Gondoic acid (ALA) ALA 9c12c15c-18:3 n3 11.72 8.01 9.81 Gondoic acid 11c-20:1 n9 1.12 0.77 0.6 Staridonic acid 11c-20:2 n9 1.12 0.7 0.6 Staridonic acid 11c1-20:2 n9 1.12 0.7 0.6 Staridonic acid 11c1-20:2 n9 1.12 0.7 0.6 Staridonic acid 11c1-20:2 n6 3.05 1.01 1 Eicosadienola cid 12c1-2-20:3 n3 0.28 0.06 0.7 Arachidonic acid 12c1-	Stearic acid	18:00	17.58	10.78	12.13
Oleic acid 9c-18:1 n9 104.16 76.08 84.49 Vaccenic acid 11c-18:1 n7 8.59 6.35 8.3 Petroselinic acid 13c-18:1 n5 0.23 0.21 0.17 Linoleic acid (trans. cis isomer) 9t12c-182 n6 0.22 0.21 0.17 Linoleic acid (GLA) 6c9t12c-18:3 n6 198 0.74 0.7 Arachidic acid (GLA) 6c9t12c-18:3 n6 198 0.74 0.7 Alpha-linolenic acid (GLA) 6c9t12c-18:3 n3 11.72 8.01 9.81 Gondoic acid 8c-20:1 n12 0 0 0 0 11-Eicosenoic acid 11c-20:1 n9 1.12 0.77 0.6 Steardonic acid 122:00 0.23 0.20 0.22 Dihomo-gamma-linolenic acid (DGLA) 8c11c14c-20:3 n5 0.35 1.01 1 Eicosatienoic acid 126-22:2 n6 0.14 0.30 0 0 Docosatienoic acid 126-22:2 n6 0.14 0.33 0 0 Eico	Trans-vaccenic acid	11t-18:1 n7	0.41	0.41	0.36
Vaccenic acid 11c-18:1 n7 8.59 6.35 8.3 Petroselinic acid 13c-18:1 n5 0.23 0.14 0.19 Conjugated linoleic acid (trans. cis isomer) 9112c-18:2 n6 0.22 0.21 0.17 Linoleic acid LA 9c12c-18:2 n6 0.22 0.21 0.19 0.21 Gamma-linolenic acid (GLA) 6c9c12c-18:3 n6 1.98 0.74 0.7 Alpha-linolenic acid (ALA) ALA 9c12c15c-18:3 n3 1.172 8.01 9.81 Gondoic acid 8c-20:1 n2 0 0 0 0 11-Eirosenoic acid 11c-20:1 n9 1.12 0.77 0.6 Stearidonic acid 6c9c12c15c-18:4 n3 0.31 0.01 0 Eicosatrienoic acid 11c1c4c-20:2 n6 4.16 1.6 1.36 Behenic acid 2200 0.23 0.22 0.22 0 0.06 0.07 Arachidonic acid AA 5c8c11c14c-20:3 n3 0.28 0.06 0.01 0 0 0 0 0 0	Oleic acid	9c-18:1 n9	104.16	76.08	84.49
Petroselinic acid 13c-18:1 n5 0.23 0.14 0.19 Conjugated linoleic acid (trans. cis isomer) 912c-18:2 n6 0.22 0.21 0.17 Linoleic acid LA 9c12c-18:2 n6 168.27 123.47 147.53 Arachidic acid (GLA) 6c9c12c-18:3 n6 1.98 0.74 0.7 Alpha-linolenic acid (GLA) 6c9c12c-18:3 n3 11.72 8.01 9.81 Gondoic acid 11c-20:1 n9 1.12 0.7 0.6 Staridonic acid 11c4c-20:2 n6 4.16 1.6 1.35 Behenic acid 22:00 0.23 0.2 0.22 Dihomo-gamma-linolenic acid (DGLA) 8c11c14c-20:3 n3 0.38 0.06 0.07 Arachidonic acid AA 5c8c11c14c-20:3 n3 0.28 0.06 0.07 Arachidonic acid IBC 12:6 0.22 n.02 0.22 Dihomo-gamma-linolenic acid (DGLA) 8c11c14c-70:2:3 n3 0.89 0.01 0.23 Eicosapertaenoic acid IBC 2:400:00 0.53 0.34 0.	Vaccenic acid	11c-18:1 n7	8.59	6.35	8.3
Conjugated linoleic acid (trans. cis isomer) 9112c-18:2 n6 0.22 0.21 0.17 Linoleic acid LA 9c12c-18:2 n6 168.27 123.47 147.53 Arachidic acid 20:00 0.21 0.19 0.21 Gamma-linolenic acid (GLA) 6c9c12c-18:3 n6 1.98 0.74 0.7 Alpha-linolenic acid (ALA) ALA 9c12c15c-18:3 n3 1.172 8.01 9.81 Gondoic acid 8c-20:1 n12 0 0 0 0 11-Eicosenoic acid 11c-20:1 n9 1.12 0.77 0.6 Stearidonic acid 6c9c12c15c-18:4 n3 0.31 0.01 0 Eicosadienoic acid 11c14c-20:2 n6 4.16 1.36 Behenic acid 0200 0.23 0.20 0.22 Dihomo-gamma-linolenic acid (DGLA) 8c11c14c-20:3 n3 0.28 0.06 0.7 Arachidonic acid A 5c8c11c14c17c-20:3 n3 0.28 0.01 0.23 Lignoceric acid 24:00:00 0.53 0.34 0.38 Clupanodonic acid	Petroselinic acid	13c-18:1 n5	0.23	0.14	0.19
Linoleic acidLA 9c12c-18:2 n6168.27123.47147.53Arachidic acid20:000.210.190.21Gamma-linolenic acid (GLA)6c9c12c-18:3 n61.980.740.7Alpha-linolenic acid (ALA)ALA 9c12c15c-18:3 n31.728.019.81Gondoic acid8c-20:1 n12000011-Eicosenoic acid11c-20:1 n91.120.700.62Stearidonic acid6c9c12c15c-18:4 n30.310.010Eicosadienoic acid11c14c-20:2 n64.161.61.36Behenic acid22:000.230.200.230.20Dihom-gamma-linolenic acid (DGLA)8c11c14c-20:3 n63.051.011Eicosatrienoic acidAA 5c8c11c14c-20:4 n611.895.857.08Docosadienoic acid13c16c-22:2 n60.140.3300Eicosapentaenoic acid (EPA)EPA 5c8c11c14c17c-20:5 n30.890.010.23Lignoceric acid13c16c-22:3 n3000.060.11Nervonic acid7c10c13c16c-22:4 n63.381.441.71Docosapentaenoic acid (DPA.n6)4c7c10cx13c16c-22:5 n61.020.560.57Docosapentaenoic acid (DPA.n3)DPA 7c10c13c16c19c-22:5 n32.150.161.34Docosapentaenoic acid (DPA.n3)DPA 7c10c13c16c19c-22:5 n32.150.161.35Docosapentaenoic acid (DPA.n3)DPA 7c10c13c16c19c-22:5 n32.151.161.35Docosapentaenoic acid (DP	Conjugated linoleic acid (trans. cis isomer)	9t12c-18:2 n6	0.22	0.21	0.17
Arachidic acid 20:00 0.21 0.19 0.21 Gamma-linolenic acid (GLA) 6c9c12c-18:3 n6 1.98 0.74 0.7 Alpha-linolenic acid (ALA) ALA 9c12c15c-18:3 n3 11.72 8.01 9.81 Gondoic acid 8c-20:1 n12 0 0 0 0 11-Eicosenoic acid 11c-20:1 n9 1.12 0.77 0.66 Stearidonic acid 6c9c12c15c-18:4 n3 0.31 0.01 0 Eicosadienoic acid 11c14c-20:2 n6 4.16 1.6 1.36 Behenic acid 22:00 0.23 0.2 0.22 0.22 Dihomo-gamma-linolenic acid (DGLA) 8c11c14c-20:3 n6 3.05 1.01 1 Eicosatrienoic acid 13c16c-22: n6 0.14 0.03 0 Eicosapentaenoic acid (EPA) EPA 5c8c11c14c17c-20:5 n3 0.89 0.01 0.23 Lignoceric acid 13c16c19c-22:3 n5 0 0.66 0.11 Nervonic acid 15c-24:1 n9 0.2 0.15 0.16 Ad	Linoleic acid	LA 9c12c-18:2 n6	168.27	123.47	147.53
Gamma-linolenic acid (GLA) 6c9c12c-18:3 n6 1.98 0.74 0.7 Alpha-linolenic acid (ALA) ALA 9c12c15c-18:3 n3 11.72 8.01 9.81 Gondoic acid 8c-20:1 n12 0 0 0 11-Eicosenoic acid 11c-20:1 n9 1.12 0.77 0.6 Stearidonic acid 6c9c12c15c-18:4 n3 0.31 0.01 0 Eicosadienoic acid 11c14c-20:2 n6 4.16 1.6 1.36 Behenic acid 22:00 0.23 0.2 0.22 0.2 0.10 1 Eicosadirenoic acid QCD 0.23 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.1 1 1 0 0.2 0.2 0.2 0.2 0.15 0.16 0.7 Narchidonic acid 0.4 0.3 0.2 0.2 0.15 0.16 0.3 0.1 0.2 0.2 0.15 0.16 0.2	Arachidic acid	20:00	0.21	0.19	0.21
Alpha-linolenic acid (ALA) ALA 9c12c15c-18:3 n3 11.72 8.01 9.81 Gondoic acid 8c-20:1 n12 0 0 0 11-Eicosenoic acid 11c-20:1 n9 1.12 0.77 0.6 Stearidonic acid 6c9c12c15c-18:4 n3 0.31 0.01 0 Eicosadienoic acid 11c14c-20:2 n6 4.16 1.6 1.36 Behenic acid 22:00 0.23 0.2 0.22 Dihomo-gamma-linolenic acid (DGLA) 8c11c14c-20:3 n6 1.08 0.06 0.07 Arachidonic acid AA 5c8c11c14c-20:4 n6 11.89 5.85 7.08 Docosadienoic acid (EPA) EPA 5c8c11c14c17c-20:5 n3 0.89 0.01 0.23 Lignoceric acid 13c16c-22:2 n6 0.14 0.03 0 Revonic acid 13c16c-22:3 n3 0 0.66 0.17 Nervonic acid 15c-24:1 n9 0.2 0.57 0.57 Docosapentaenoic acid (DPA.n6) Ac7c10c13c16c-22:5 n3 1.0 0.7 0.86 Docosapentaenoic acid (DP	Gamma-linolenic acid (GLA)	6c9c12c-18:3 n6	1.98	0.74	0.7
Condoic acid 8c-20:1 n12 0 0 0 11-Eicosenoic acid 11c-20:1 n9 1.12 0.77 0.6 Stearidonic acid 6c9C12c15c-18:4 n3 0.31 0.01 0 Eicosadienoic acid 11c14c-20:2 n6 4.16 1.6 1.36 Behenic acid 22:00 0.23 0.2 0.22 Dihomo-gamma-linolenic acid (DGLA) 8c11c14c-20:3 n3 0.36 0.01 1 Eicosatrienoic acid AA 5c8c11c14c-20:4 n6 11.89 5.85 7.08 Docosadienoic acid 13c16c-22:2 n6 0.14 0.03 0 Eicosapentaenoic acid (EPA) EPA 5c8c11c14c17c-20:5 n3 0.89 0.01 0.23 Lignoceric acid 13c16c19c-22:3 n3 0 0.66 0.1 Nervonic acid 15c-24:1 n9 0.2 0.15 0.16 Adrenic acid 7c10c13c16c19c-22:5 n3 2.15 0.7 0.86 Docosapentaenoic acid (DPA.n6) DPA 7c10c13c16c19c-22:5 n3 2.15 0.7 0.86 Docosapentaenoic acid	Alpha-linolenic acid (ALA)	ALA 9c12c15c-18:3 n3	11.72	8.01	9.81
11-Eicosenoic acid11c-20:1 n91.120.770.6Stearidonic acid6c9c12c15c-18:4 n30.310.010Eicosadienoic acid11c14c-20:2 n64.161.61.36Behenic acid22:000.230.20.22Dihomo-gamma-linolenic acid (DGLA)8c11c14c-20:3 n63.051.011Eicosatrienoic acidAA 5c8c11c14c-20:4 n611.895.857.08Docosadienoic acid13c16c-22:2 n60.140.030Eicosapentaenoic acid (EPA)EPA 5c8c11c14c7c-0:5 n30.890.010.23Lignoceric acid2400.000.530.340.380.14Clupanodonic acid13c16c-22:3 n300.060.1Nervonic acid15c-24:1 n90.20.150.16Adrenic acid7c10c13c16c-22:4 n63.381.441.71Docosapentaenoic acid (DPA. n6)4c7c10c13c16c19c-22:5 n32.150.70.86Docosahexaenoic acid (DPA. n3)DPA 7c10c13c16c19c-22:5 n32.150.70.86Docosahexaenoic acid (DPA. n3)DPA 7c10c13c16c19c-22:5 n31.161.43Categories1.020.571.61Total omega-3 fatty acids to omega-6 fatty acidsn-31 n-60.10.70.86Total omega-3 fatty acids to saturated fatty acidsn-31 n-61.021.571.62Total omega-3 fatty acids to saturated fatty acidsSaturated2.80,711.770.57Cis polyunsaturated omega-3 fatty ac	Gondoic acid	8c-20:1 n12	0	0	0
Stearidonic acid 669212c15c-18:4 n3 0.31 0.01 0 Eicosadienoic acid 11c14c-20:2 n6 4.16 1.6 1.36 Behenic acid 22:00 0.23 0.2 0.22 Dihomo-gamma-linolenic acid (DGLA) 8c11c14c-20:3 n6 3.05 1.01 1 Eicosatrienoic acid AA 5c8c11c14c-20:4 n6 11.89 5.85 7.08 Docosadienoic acid 13c16c-22:2 n6 0.14 0.03 0 Eicosapentaenoic acid (EPA) EPA 5c8c11c14c17c-20:5 n3 0.89 0.01 0.23 Lignoceric acid 24:00:00 0.53 0.34 0.38 Clupanodonic acid 15c-24:1 n9 0.2 0.15 0.16 Adrenic acid 7c10c13c16c-22:4 n6 3.38 1.44 1.71 Docosapentaenoic acid (DPA. n6) 4c7c10cx13c16c-19c-22:5 n3 0.15 0.57 Docosapentaenoic acid (DPA. n6) DHA 4c7c10c13c16c19c-22:6 n3 0.5 1.61 1.43 Categories	11-Eicosenoic acid	11c-20:1 n9	1.12	0.77	0.6
Eicosadienoic acid11c14c-20:2 n64.161.61.36Behenic acid22:000.230.20.22Dihomo-gamma-linolenic acid (DGLA)8c11c14c-20:3 n63.051.011Eicosatrienoic acidAA 5c8c11c14c-20:3 n30.280.060.07Arachidonic acidAA 5c8c11c14c-20:4 n611.895.857.08Docosadienoic acid13c16c-22:2 n60.140.030Eicosapentaenoic acid (EPA)EPA 5c8c11c14c17c-20:5 n30.890.010.23Lignoceric acid24:00:000.530.340.38Clupanodonic acid13c16c-22:3 n300.060.1Nervonic acid15c-24:1 n90.20.150.16Adrenic acid7c10c13c16c-22:4 n63.381.441.71Docosapentaenoic acid (DPA. n6)PA 7c10c13c16c19c-22:5 n30.70.86Docosapentaenoic acid (DPA. n3)DPA 7c10c13c16c19c-22:5 n32.51.161.43CategoriesItal acidsn-3/n-60.10.070.88Total omega-3 fatty acids to omega-6 fatty acidsn-3 fotal19.510.0512.58Saturated fatty acidsn-3 total19.0510.0512.52Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis19.0410.0512.52Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n5 cis19.371.46159.96Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n5 cis19.371.44159.96	Stearidonic acid	6c9c12c15c-18:4 n3	0.31	0.01	0
Behenic acid22:000.230.20.22Dihomo-gamma-linolenic acid (DGLA)8c11c14c-20:3 n63.051.011Eicosatrienoic acidETE 11c14c17c-20:3 n30.280.060.07Arachidonic acidAA 5c8c11c14c-20:4 n611.895.857.08Docosadienoic acid13c16c-22:2 n60.140.030Eicosapentaenoic acid (EPA)EPA 5c8c11c14c17c-20:5 n30.890.010.23Lignoceric acid24:00:000.530.340.38Clupanodonic acid15c-24:1 n90.20.150.16Adrenic acid7c10c13c16c-22:4 n63.381.441.71Docosapentaenoic acid (DPA. n6)4c7c10c13c16c-22:5 n30.70.86Docosapentaenoic acid (DPA. n5)DPA 7c10c13c16c19c-22:5 n31.161.43Docosapentaenoic acid (DPA. n3)DPA 7c10c13c16c19c-22:5 n31.161.43Docosapentaenoic acid (DPA. n5)n-90.21.171.58Saturated1194.17134.88160.121.051.55Saturated intragisn-90.21.051.258Saturated fatty acidsn-90.91.371.77Cis polyunsaturated fatty acidsPolyunsaturated n3 cis19.0410.0512.52<	Eicosadienoic acid	11c14c-20:2 n6	4.16	1.6	1.36
Dihomo-gamma-linolenic acid (DGLA)8c11c14c-20:3 n63.051.011Eicosatrienoic acidETE 11c14c17c-20:3 n30.280.060.07Arachidonic acidAA 5c8c11c14c-20:4 n611.895.857.08Docosadienoic acid (EPA)EPA 5c8c11c14c17c-20:5 n30.890.010.23Lignoceric acid24:00:000.530.340.38Clupanodonic acid13c16c19c-22:3 n300.060.1Nervonic acid15c-24:1 n90.20.150.16Adrenic acid (DPA. n6)4c7c10c13c16c-22:5 n61.020.50.57Docosapentaenoic acid (DPA. n6)DPA 7c10c13c16c19c-22:5 n32.150.70.86Docosapentaenoic acid (DPA. n3)DPA 7c10c13c16c19c-22:5 n32.150.70.86Docosahexaenoic acid (DHA)DHA 4c7c10c13c16c19c-22:5 n32.151.161.43CategoriesRatio of omega-3 fatty acids to omega-6 fatty acidsn-3/n-60.10.070.08Total omega-3 fatty acidsn-3/n-60.110.070.88Saturated fatty acidsn-3 total19.0510.0512.58Saturated fatty acidsSaturated268.07107.7696.71Ratio of polyunsaturated fatty acidsPolyunsaturated n3 cis19.0410.0512.52Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis19.3713.464159.96Total omega-6 fatty acidsPolyunsaturated n3 cis193.7913.464159.96Tians polyunsaturat	Behenic acid	22:00	0.23	0.2	0.22
Eicosatrienoic acid ETE 11cl4c17c-20:3 n3 0.28 0.06 0.07 Arachidonic acid AA 5c8c11c14c-20:4 n6 11.89 5.85 7.08 Docosadienoic acid 13c16c-22:2 n6 0.14 0.03 0 Eicosapentaenoic acid (EPA) EPA 5c8c11c14c17c-20:5 n3 0.89 0.01 0.23 Lignoceric acid 24:00:00 0.53 0.34 0.38 Clupanodonic acid 13c16c19c-22:3 n3 0 0.06 0.1 Nervonic acid 7c10c13c16c-22:4 n6 3.38 1.44 1.71 Docosapentaenoic acid (DPA. n6) 4c7c10cx13c16c-22:5 n6 1.02 0.57 0.86 Docosapentaenoic acid (DPA. n3) DPA 7c10c13c16c19c-22:5 n3 2.15 0.7 0.86 Docosapentaenoic acid (DPA. n3) DPA 7c10c13c16c19c-22:5 n3 2.15 1.14 1.43 Categories 0.7 0.86 0.12 1.44 Total omega-3 fatty acids to omega-6 fatty acids n-3/n-6 0.1 0.07 0.08 Total omega-3 fatty acids n-3/n-6	Dihomo-gamma-linolenic acid (DGLA)	8c11c14c-20:3 n6	3.05	1.01	1
Arachidonic acid AA 5c8c11c14c-20:4 n6 11.89 5.85 7.08 Docosadienoic acid 13c16c-22:2 n6 0.14 0.03 0 Eicosapentaenoic acid (EPA) EPA 5c8c11c14c17c-20:5 n3 0.89 0.01 0.23 Lignoceric acid 24:00:00 0.53 0.34 0.38 Clupanodonic acid 13c16c19c-22:3 n3 0 0.06 0.1 Nervonic acid 15c-24:1 n9 0.2 0.15 0.16 Adrenic acid 7c10c13c16c-22:4 n6 3.38 1.44 1.71 Docosapentaenoic acid (DPA. n6) 4c7c10cx13c16c-22:5 n6 1.02 0.5 0.57 Docosahexaenoic acid (DPA. n3) DPA 7c10c13c16c19c-22:5 n3 2.15 0.7 0.86 Categories 144 1.71 134.88 160.12 Total omega-3 fatty acids to omega-6 fatty acids n-3/n-6 0.1 0.07 0.88 Total omega-3 fatty acids to saturated fatty acids n-3 total 190.5 10.05 12.58 Saturated fatty acids Saturated 190	Eicosatrienoic acid	ETE 11c14c17c-20:3 n3	0.28	0.06	0.07
Docosadienoic acid 13c16c-22:2 n6 0.14 0.03 0 Eicosapentaenoic acid (EPA) EPA 5c8c11c14c17c-20:5 n3 0.89 0.01 0.23 Lignoceric acid 24:00:00 0.53 0.34 0.38 Clupanodonic acid 13c16c19c-22:3 n3 0 0.06 0.1 Nervonic acid 15c-24:1 n9 0.2 0.15 0.16 Adrenic acid 7c10c13c16c-22:5 n6 1.02 0.57 0 Docosapentaenoic acid (DPA. n6) 4c7c10cx13c16c-22:5 n3 2.15 0.7 0.86 Docosahexaenoic acid (DPA. n3) DPA 7c10c13c16c19c-22:6 n3 2.5 1.16 1.43 Categories 0.16 0.07 0.08 Total omega-3 fatty acids to omega-6 fatty acids n-3/n-6 0.1 0.07 0.08 Total omega-6 fatty acids n-3/n-6 0.1 0.07 0.88 Saturated fatty acids n-3 total 19.05 12.58 12.58 Saturated fatty acids Saturated 268.07 10.77 96.71	Arachidonic acid	AA 5c8c11c14c-20:4 n6	11.89	5.85	7.08
Eicosapentaenoic acid (EPA) EPA 5c8c11c14c17c-20:5 n3 0.89 0.01 0.23 Lignoceric acid 24:00:00 0.53 0.34 0.38 Clupanodonic acid 13c16c19c-22:3 n3 0 0.06 0.1 Nervonic acid 15c-24:1 n9 0.2 0.15 0.16 Adrenic acid 7c10c13c16c-22:4 n6 3.38 1.44 1.71 Docosapentaenoic acid (DPA. n6) 4c7c10cx13c16c-22:5 n3 2.15 0.7 0.86 Docosahexaenoic acid (DPA. n3) DPA 7c10c13c16c19c-22:6 n3 2.15 1.16 1.43 Categories 0.11 0.07 0.08 Total omega-3 fatty acids to omega-6 fatty acids n-3/n-6 0.1 0.07 0.08 Total omega-3 fatty acids n-3 total 19.05 10.05 12.58 Saturated fatty acids n-3 total 19.05 10.05 12.52 Cis polyunsaturated omega-3 fatty acids Saturated n3 cis 19.04 10.05 12.52 Cis polyunsaturated omega-3 fatty acids Polyunsaturated n3 cis <	Docosadienoic acid	13c16c-22:2 n6	0.14	0.03	0
Lignoceric acid 24:00:00 0.53 0.34 0.38 Clupanodonic acid 13c16c19c-22:3 n3 0 0.06 0.1 Nervonic acid 15c-24:1 n9 0.2 0.15 0.16 Adrenic acid 7c10c13c16c-22:4 n6 3.38 1.44 1.71 Docosapentaenoic acid (DPA. n6) 4c7c10cx13c16c-22:5 n6 1.02 0.5 0.57 Docosapentaenoic acid (DPA. n3) DPA 7c10c13c16c19c-22:6 n3 2.15 0.7 0.86 Docosahexaenoic acid (DHA) DHA 4c7c10c13c16c19c-22:6 n3 2.5 1.16 1.43 Categories 0.1 0.07 0.08 Total omega-3 fatty acids to omega-6 fatty acids n-3/n-6 0.1 0.07 0.08 Total omega-6 fatty acids n-3 total 19.05 10.05 12.58 Saturated fatty acids n-3 total 19.05 10.05 12.52 Cis polyunsaturated omega-3 fatty acids Saturated 268.07 107.76 96.71 Ratio of polyunsaturated omega-3 fatty acids Polyunsaturated n3 cis <	Eicosapentaenoic acid (EPA)	EPA 5c8c11c14c17c-20:5 n3	0.89	0.01	0.23
Cupanodonic acid 13c16c19c-22:3 n3 0 0.06 0.1 Nervonic acid 15c-24:1 n9 0.2 0.15 0.16 Adrenic acid 7c10c13c16c-22:4 n6 3.38 1.44 1.71 Docosapentaenoic acid (DPA. n6) 4c7c10cx13c16c-22:5 n6 1.02 0.5 0.57 Docosapentaenoic acid (DPA. n3) DPA 7c10c13c16c19c-22:5 n3 2.15 0.7 0.86 Docosahexaenoic acid (DHA) DHA 4c7c10c13c16c19c-22:6 n3 2.5 1.16 1.43 Categories 0.1 0.07 0.08 Total omega-3 fatty acids to omega-6 fatty acids n-3/n-6 0.1 0.07 0.08 Total omega-3 fatty acids n-6 total 194.17 134.88 160.12 Total omega-6 fatty acids saturated 268.07 107.76 96.71 Ratio of polyunsaturated fatty acids to saturated fatty acids Saturated n3 cis 19.04 10.05 12.52 Cis polyunsaturated omega-3 fatty acids Polyunsaturated n3 cis 19.04 10.05 12.52 Cis polyunsaturated omega-6 fatty acids </td <td>Lignoceric acid</td> <td>24:00:00</td> <td>0.53</td> <td>0.34</td> <td>0.38</td>	Lignoceric acid	24:00:00	0.53	0.34	0.38
Nervonic acid 15c-24:1 n9 0.2 0.15 0.16 Adrenic acid 7c10c13c16c-22:4 n6 3.38 1.44 1.71 Docosapentaenoic acid (DPA. n6) 4c7c10cx13c16c-22:5 n6 1.02 0.5 0.57 Docosapentaenoic acid (DPA. n3) DPA 7c10c13c16c19c-22:5 n3 2.15 0.7 0.86 Docosahexaenoic acid (DHA) DHA 4c7c10c13c16c19c-22:6 n3 2.5 1.16 1.43 Categories	Clupanodonic acid	13c16c19c-22:3 n3	0	0.06	0.1
Adrenic acid 7c10c13c16c-22:4 n6 3.38 1.44 1.71 Docosapentaenoic acid (DPA. n6) 4c7c10cx13c16c-22:5 n6 1.02 0.5 0.57 Docosapentaenoic acid (DPA. n3) DPA 7c10c13c16c19c-22:5 n3 2.15 0.7 0.86 Docosahexaenoic acid (DHA) DHA 4c7c10c13c16c19c-22:6 n3 2.5 1.16 1.43 Categories	Nervonic acid	15c-24:1 n9	0.2	0.15	0.16
Docosapentaenoic acid (DPA. n6)4c7c10cx13c16c-22:5 n61.020.50.57Docosapentaenoic acid (DPA. n3)DPA 7c10c13c16c19c-22:5 n32.150.70.86Docosahexaenoic acid (DHA)DHA 4c7c10c13c16c19c-22:6 n32.51.161.43CategoriesRatio of omega-3 fatty acids to omega-6 fatty acidsn-3/n-60.10.070.08Total omega-3 fatty acidsn-6 total194.17134.88160.12Total omega-6 fatty acidsn-3 total19.0510.0512.58Saturated fatty acidsSaturated268.07107.7696.71Ratio of polyunsaturated fatty acids to saturated fatty acidsP (n-3 & 6)/S0.791.371.77Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis19.0410.0512.52Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis0.000Trans polyunsaturated fatty acidsCis monounsaturated n6 trans0.280.230.17Trans monounsaturated fatty acidsTrans monounsaturated n6 trans10.740.7913.26ContinuedCis monounsaturated fatty acidsCis monounsaturated n6 trans12.64159.96	Adrenic acid	7c10c13c16c-22:4 n6	3.38	1.44	1.71
Image: Constraint of the constra	Docosapentaenoic acid (DPA, n6)	4c7c10cx13c16c-22:5 n6	1.02	0.5	0.57
Docosahexaenoic acid (DHA)DHA 4c7c10c13c16c19c-22:6 n32.51.161.43CategoriesRatio of omega-3 fatty acids to omega-6 fatty acidsn-3/n-60.10.070.08Total omega-3 fatty acidsn-6 total194.17134.88160.12Total omega-6 fatty acidsn-3 total19.0510.0512.58Saturated fatty acidsSaturated268.07107.7696.71Ratio of polyunsaturated fatty acids to saturated fatty acidsP (n-3 & 6)/S0.791.371.77Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis19.0410.0512.52Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n3 trans000Trans monounsaturated fatty acidsTrans monounsaturated n6 trans0.280.230.17Cis monounsaturated fatty acidsCis monounsaturated n10.740.7913.26	Docosapentaenoic acid (DPA, n3)	DPA 7c10c13c16c19c-22:5 n3	2.15	0.7	0.86
CategoriesRatio of omega-3 fatty acids to omega-6 fatty acidsn-3/n-60.10.070.08Total omega-3 fatty acidsn-6 total194.17134.88160.12Total omega-6 fatty acidsn-3 total19.0510.0512.58Saturated fatty acidsSaturated268.07107.7696.71Ratio of polyunsaturated fatty acids to saturated fatty acidsP (n-3 & 6)/S0.791.371.77Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis190.410.0512.52Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n3 trans000Trans polyunsaturated atty acidsPolyunsaturated n6 trans0.280.230.17Trans monounsaturated fatty acidsTrans monounsaturated10.740.79Cis monounsaturated fatty acidsCis monounsaturated127.4896.3107.26	Docosahexaenoic acid (DHA)	DHA 4c7c10c13c16c19c-22:6 n3	2.5	1.16	1.43
Ratio of omega-3 fatty acids to omega-6 fatty acidsn-3/n-60.10.070.08Total omega-3 fatty acidsn-6 total194.17134.88160.12Total omega-6 fatty acidsn-3 total19.0510.0512.58Saturated fatty acidsSaturated268.07107.7696.71Ratio of polyunsaturated fatty acids to saturated fatty acidsP (n-3 & 6)/S0.791.371.77Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis190.4410.0512.52Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n3 trans000Trans polyunsaturated fatty acidsPolyunsaturated n6 trans0.280.230.17Trans monounsaturated fatty acidsTrans monounsaturated10.740.79Cis monounsaturated fatty acidsCis monounsaturated127.4896.3107.26	Categories				
Total omega-3 fatty acidsn-6 total194.17134.88160.12Total omega-6 fatty acidsn-3 total19.0510.0512.58Saturated fatty acidsSaturated268.07107.7696.71Ratio of polyunsaturated fatty acids to saturated fatty acidsP (n-3 & 6)/S0.791.371.77Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis19.0410.0512.52Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-3 fatty acidsPolyunsaturated n3 trans000Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n6 trans0.280.230.17Trans monounsaturated fatty acidsTrans monounsaturated 10.740.79Cis monounsaturated fatty acids127.4896.3107.26	Ratio of omega-3 fatty acids to omega-6 fatty acids	n-3/n-6	0.1	0.07	0.08
Total omega-6 fatty acidsn-3 total19.0510.0512.58Saturated fatty acidsSaturated268.07107.7696.71Ratio of polyunsaturated fatty acids to saturated fatty acidsP (n-3 & 6)/S0.791.371.77Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis19.0410.0512.52Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-3 fatty acidsPolyunsaturated n3 trans000Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n6 trans0.280.230.17Trans monounsaturated fatty acidsTrans monounsaturated 10.740.79Cis monounsaturated fatty acids127.4896.3107.26	Total omega-3 fatty acids	n-6 total	194.17	134.88	160.12
SaturatedSaturatedSaturatedSaturatedSaturatedSaturated fatty acidsSaturatedSaturated268.07107.7696.71Ratio of polyunsaturated fatty acids to saturated fatty acidsP (n-3 & 6)/S0.791.371.77Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis19.0410.0512.52Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-3 fatty acidsPolyunsaturated n3 trans000Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n6 trans0.280.230.17Trans monounsaturated fatty acidsTrans monounsaturated10.740.79Cis monounsaturated fatty acidsCis monounsaturated127.4896.3107.26	Total omega-6 fatty acids	n-3 total	19.05	10.05	12.58
Ratio of polyunsaturated fatty acids to saturated fatty acidsP (n-3 & 6)/S0.791.371.77Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis19.0410.0512.52Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-3 fatty acidsPolyunsaturated n3 trans000Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n3 trans0.280.230.17Trans monounsaturated omega-6 fatty acidsTrans monounsaturated n6 trans0.280.230.17Trans monounsaturated fatty acidsTrans monounsaturated10.740.79Cis monounsaturated fatty acidsCis monounsaturated127.4896.3107.26	Saturated fatty acids	Saturated	268.07	107.76	96.71
Cis polyunsaturated omega-3 fatty acidsPolyunsaturated n3 cis19.0410.0512.52Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-3 fatty acidsPolyunsaturated n3 trans000Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n6 trans0.280.230.17Trans monounsaturated atty acidsTrans monounsaturated n6 trans0.740.79Cis monounsaturated fatty acidsCis monounsaturated127.4896.3107.26ContinuedContinuedContinuedContinuedContinuedContinued	Ratio of polyunsaturated fatty acids to saturated fatty acids	P (n-3 & 6)/S	0.79	1.37	1.77
Cis polyunsaturated omega-6 fatty acidsPolyunsaturated n6 cis193.79134.64159.96Trans polyunsaturated omega-3 fatty acidsPolyunsaturated n3 trans000Trans polyunsaturated omega-6 fatty acidsPolyunsaturated n6 trans0.280.230.17Trans monounsaturated fatty acidsTrans monounsaturated n6 trans0.740.79Cis monounsaturated fatty acidsCis monounsaturated127.4896.3107.26ContinuedContinuedContinuedContinuedContinuedContinued	Cis polyunsaturated omega-3 fatty acids	Polyunsaturated n3 cis	19.04	10.05	12.52
Trans polyunsaturated omega-3 fatty acidsPolyunsaturated no clasDSDFDSDFDSDFTrans polyunsaturated omega-3 fatty acidsPolyunsaturated n3 trans000Trans monounsaturated omega-6 fatty acidsPolyunsaturated n6 trans0.280.230.17Trans monounsaturated fatty acidsTrans monounsaturated10.740.79Cis monounsaturated fatty acidsCis monounsaturated127.4896.3107.26	Cis polyunsaturated omega-6 fatty acids	Polyunsaturated n6 cis	193.79	134.64	159.96
Trans polyunsaturated omega-6 fatty acidsPolyunsaturated no tunis000Trans monounsaturated fatty acidsPolyunsaturated no trans0.280.230.17Cis monounsaturated fatty acidsTrans monounsaturated10.740.79Cis monounsaturated fatty acidsCis monounsaturated127.4896.3107.26	Trans polyunsaturated omega-3 fatty acids	Polyunsaturated n3 trans	0	0	0
Trans monounsaturated fatty acids Trans monounsaturated 1 0.74 0.79 Cis monounsaturated fatty acids Cis monounsaturated 127.48 96.3 107.26	Trans polyunsaturated omega-6 fatty acids	Polyunsaturated n6 trans	0.28	0.23	0.17
Cis monounsaturated fatty acids Cis monounsaturated 1 0.74 0.75 Continued Cis monounsaturated 127.48 96.3 107.26	Trans monounsaturated fatty acids	Trans monounsaturated	1	0.74	0.79
Continued	Cis monounsaturated fatty acids	Cis monounsaturated	127 48	96 3	107.26
Continued	Continued			1	L

Fatty Acids	Carboxyl nomenclature	PND21	PND46	PND90
		Mean (mg FA/g)		
Cis monounsaturated omega-6 fatty acids	Monounsaturated n6 cis	0	0	0
Total trans fatty acids	Total trans	1.29	0.97	1.02
Total cis fatty acids	Total cis	340.4	240.99	279.74
Total cis omega-6 fatty acids	Total omega-6 cis	193.89	134.65	159.95
Total Fatty acids	Total Fatty acids	610.02	349.87	377.67

Table 1. The changes in fatty acid components across developmental stages.

fluidity, and cellular signaling, which are vital during developmental processes²⁶. In addition, total omega-6 and omega-3 are related to inflammatory processes, acting as precursors to pro-inflammatory eicosanoids and being essential for cell growth, membrane integrity, and immune signaling pathways (Fig. 5D). In contrast, during the transition from PND46 to PND90, there was no significant alteration in the categories of fatty acids. Current data suggest modulation at the transcriptional and relative expression level as well as from alterations in lipid levels.

The fatty acids were then studied individually to determine which ones were deregulated during the different stages of mammary development. Significant changes were observed in the concentrations of saturated fatty acids, such as palmitic acid, which decreased during the transition from PND21 to PND46 but did not show significant deregulation between the transition from PND46 to PND90 (Fig. S5A). Palmitic acid is one of the main components of the cell membrane, responding to the increased proliferation of epithelial cells during the formation of TEBs²⁷. A similar pattern was observed when investigating unsaturated fatty acids. Linoleic, oleic, arachidonic, vaccenic, adrenic, dihomo-gamma-linolenic, and eicosadienoic acids were downregulated during the transition from pre-puberty to peri-puberty only (Fig. S5B). These unsaturated fatty acids are involved in cell growth, cell membrane structure, membrane fluidity, cell signaling, and immune response²⁸.

For other saturated fatty acids, such as caprylic, capric, lauric, myristic, and stearic acids, we observed a significant decrease during the transition from PND21 to PND46 and again from PND46 to PND90 (Fig. S5A). These fatty acids participate in processes that provide energy for rapidly growing mammary tissue cells, transport proteins, tissue maintenance, and repair²⁹. In contrast, eicosapentaenoic acid and clupanodonic acid were upregulated during the transition from PND46 to PND90 (Fig. S5C), indicating the promotion of anti-inflammatory processes and modulation of the immune response³⁰.

Adipocyte changes across developmental stages in the stroma

To investigate whether changes in the differential expression of fatty acid metabolism genes and differential fatty acid patterns across developmental stages are reflected in morphological changes in the adipocytes present in the stromal tissue, we compared the distribution of adipocytes in terms of number and size within the tissue. During the transition between PND21 to PND46, the number of adipocytes increased, but they were smaller in size (Fig. 6A). In contrast, during the transition between PND46 and PND90, the number of adipocytes was decreased, but they were bigger in size (Fig. 5B). This could indicate a decrease in fatty acid deposits within the adipocytes, resulting in a rise in the number of adipocytes per cm² but a reduction in the size of each adipocyte compared to the PND21 and PND90 stages.

Immune response and cellular signaling dynamic across developmental stages

Another interesting finding from the transcriptomic analysis was the cluster demonstrating changes in the molecular mechanisms related to immune response and cellular signaling (Cluster 4, Fig. 2A). To further investigate the immune response, we performed a GSEA that confirmed a strong enrichment in the interferonalpha response gene set from PND21 to PND46 with a NES of -2.35 (Fig. 7A). However, during the transition from PND46 to PND90, there was no significant variation of this gene set (NES value of -0.82). We then performed an overlap analysis of cluster 4, related to immune response and cellular signaling dynamics, with the upregulated and downregulated genes in the differentially expressed gene analysis. We found that 629 genes upregulated in the transition from PND21 to PND46 were related to cluster 4. These genes included *IRF7*, involved in the interferon pathway; *Tnfrsf11a*, *Traf1*, and *Tnfip3* (TNF Alpha-Induced Protein 3), associated with the activation of the NF- κ B pathway; *Ccl4* (C-C Motif Chemokine Ligand 4) and *Ccl21* (C-C Motif Chemokine Ligand 21), chemokines related to immune cell migration and activation; and *Lag3* (Lymphocyte Activating 3), *Cd53*, *Cd84*, *Cd244*, and *Cd69*, which participate in immune cell activation (Fig. 7B). The increases expression levels during this transition were confirmed by RT-qPCR in genes including *Tnfrsf11a*, *Irf7*, *Traf1*, and *Cd3e* (Fig. S3B).

These genes were then analyzed using Metascape, which revealed, in the enrichment pathways analysis, that processes such as lymphocyte activation, B cell activation, regulation of leukocyte activation, positive regulation of immune response, adaptive immune response, leukocyte proliferation, among others, were upregulated (Fig. 7C). Additionally, in the differential gene expression analysis, GO analysis showed that molecular functions related to amide, antigen, peptide binding, and immune receptor activity were upregulated (Fig. 7D). In addition, we performed a GSEA M8 - cell type signature gene analysis, which predicts the enrichment of specific cell types. These results confirmed a strong enrichment of immune cell gene signatures, such as those linked to CD4-positive T-cells, monocytes, dendritic cells, natural killer cells, and B cells in PND46 compared to PND21 (Fig. S6A). In PND90, cell types such as antigen-presenting cells, stromal cells, CD4 T-cells, and B cells were enriched as well, maintaining the immune response between PND46 and PND90 (Fig. S6B). These results indicated





D



Fig. 5. The changes of fatty acids composition across developmental stages of the mammary gland. (**A**) Principal component analysis showing the differential distribution of the fatty acids across the groups. (**B**) In the heatmap of 41 fatty acids across developmental stages, the concentration of the lipids was clustered and represented in the rows, while the samples are represented in the columns from PND21, PND46, and PND90. (**C**) Correlation of fatty acids showing the different lipid profiles at PND21, PND46, and PND90 groups; the red color indicates a negative correlation in the interaction between lipids and the blue color indicates a positive correlation. (**D**) Histogram representation of all categories of fatty acids such as saturated fatty acids, total cis fatty acids, total omega-6 fatty acids, total omega-3 fatty acids, and ratio of omega-3 to omega-6 fatty acids. Error bars represent SD (*p < 0.05, **p < 0.01).

Scientific Reports | (2025) 15:12222



Adipocyte number

Adipocyte size



Fig. 6. Adipocyte analysis across developmental stages. (**A**) Representative image of Masson's Trichrome stained adipose tissue from PND21, PND46, and PND90 rats and of the analysis of adipocytes using the Adiposoft plugin from ImageJ. Magnification 10x, scale bar 100 μ m. (**B**) Histogram representing the number of adipocytes per cm² per group and adipocyte size in μ m². Error bars represent SD (**p* < 0.05, ****p* < 0.001).



Fig. 7. RNA-seq analyses indicate significant enrichment for immune response. (**A**) Hallmarks gene sets are shown for an interferon-a response during the transition between PND21 to PND46 and PND46 to PND90. NES; Normalized enrichment score. The red color indicates higher expression in heatmaps, and the blue color indicates lower expression. (**B**) Venn diagram for overlapping significant genes upregulated, downregulated, and cluster 4 during the transition between PND21 and PND46. (**C**) Metascape enrichment network visualization of the 629 overlapping genes notably for immune response activation. (**D**) Gene Ontology enrichment analysis of molecular function for upregulated and downregulated genes during the transition between PND21 and PND46.

that the transition from pre-pubertal to peri-pubertal stages is characterized by alterations in transcriptional signatures associated with the aforementioned biological functions.

Discussion

The development of the mammary gland has been extensively studied in various animal models, mainly focusing on epithelial tissue development, ductal branching elongation, and TEB formation¹³. Both animal and human mammary gland development follow the same sequence of events. After birth, the mammary gland experiences successive transitional stages: pre-puberty, peri-puberty, adulthood, pregnancy, lactation, post-lactational involution, and natural involution (menopause). In this study, we measured the gene expression of rat mammary glands across three development stages and its relationship with epithelial development, the lipidomic profile, and changes in mammary gland development has not been reported. Although one of the limitations of our study is the fact that whole tissue homogenates were used, thus encompassing both epithelial and stromal tissues, transcriptomic signatures suggested that important modifications were happening in the stroma.

After birth, mammary gland development remains relatively quiescent, growing at the same pace as the body, until the onset of peri-puberty³¹. During the transition from pre-puberty to peri-puberty, there is an increase in ovarian hormones such as estrogen and progesterone, as well as pituitary hormones like growth factor, which together trigger cellular proliferation, matrix remodeling, and the development of proliferative structures known as TEBs¹³. Our RNA-seq analysis revealed that during the transition between pre-puberty to peri-puberty, the gene expression patterns showed that higher expression of genes in cluster 1 was related to ECM organization, growth factor response, enzyme-linked receptor proteins signaling, and vasculature development. Using whole gland homogenates, we showed downregulation of ECM-related genes, including Col12a1, Col5a3, Lum, Dpt, Eln, Plin1, Cd44, Fab, and Itgb1bp2 during the transition between pre-puberty to peri-puberty. These findings are consistent with a reduction in stromal cells from 55 to 18% during the transition between young and aged mammary glands¹⁸. Interestingly, Li et al. have demonstrated through single-cell RNA-seq that myoepithelial and luminal cells from aged mice (13-14 months old) exhibited lower expression of ECM genes such as Dcn, Col4a1, Col4a2, Serpinh1, Sparc, Emid1, Dag, and Spon2 compared to younger glands (3-4 months old), while stromal cells in aged glands showed higher ECM gene expression¹⁸. This suggest that expression of ECM genes is not restricted to the stroma, but that can also fluctuate within epithelial cells throughout development. While the changes in ECM-related observed in our study could be explained by the proportional changes in epithelial and stromal cells during development, with the growing epithelium within the stroma leading to an overall decrease in ECM gene expression and ductal branching formation³², it cannot be excluded that it also reflect a change in transcriptional regulation in epithelial cells. Further studies are needed to verify this hypothesis.

During puberty, rats typically reach their maximum TEB count between days 21 and 28³³. From days 21 to 84, alveolar buds show a notable increase due to the action of estrogen and progesterone and their influence on transcriptional factors and signaling pathways mentioned before². The epithelial proliferation will continue until the ducts reach the edge of the fat pad, leading to changes in the stromal tissue⁴. The cellular proliferation of epithelial cells is mediated by the activation of mitogen-activated protein kinase and phosphatidylinositol-3-kinase (PI3K)-Akt pathways, which are activated by fibroblast growth factors and their receptors^{2,34}. In our analysis, adult mammary glands showed higher expression of genes related to hormonal regulation and stress responses, particularly those involved in growth factor signaling (Fgf2, Fgf7, Igf2bp2, Igf2, Ghr, and Fgfrl1), epithelial cell regulation and differentiation (Gata3, Traf1, Elf3, Ovol2, Gadd45b, and Sox9), reproductive structure development (Pgr, Areg, and Socs3), and cell morphogenesis (Gata3, Sox9, and Ovol2). These results underscore the critical role of hormonal regulation in mammary gland development, especially in response to steroid hormones that support epithelial-mesenchymal transition (EMT) in epithelial cells³⁵. In rodents, growth hormone acts directly on adipocytes, upregulating the transcription of insulin-like growth factor-1 (IGF-1), which in turn stimulates epithelial cell proliferation, resulting in ductal elongation and TEB formation³⁶. In parallel, the interaction between IGF-1 and the RhoGTPase activating (Rho-GAP) family and insulin receptor substrate-1/2 (IRS) allows for EMT³⁷. This active proliferation requires energy and building materials. In rodents, the fat pad is mainly composed of adipocytes and immune cells, which are known to have endocrine and secretion functions¹⁰. Our study found that adipocyte size decreased from pre-puberty to peri-puberty but increased as the gland transitioned to adulthood, supporting the premise that epithelial proliferation is linked with a high demand for lipids during the phase of ductal elongation, followed by the accumulation of lipids within adipocytes once the growth of the epithelium stabilizes.

Many results from our study could be attributed to metabolic regulation influenced by differential gene expression at each developmental stage. Cluster 2 genes, which were enriched for processes such as oxidative phosphorylation *Ndufc1*, *Ndufb6*, and *Uqcrb*), cell cycle (*Cdk1*, *Cenpf*, and *Bub1*), acyl-CoA metabolic process (*Acaca*, *Acss2*, and *Acsl1*), pyruvate metabolism, and the TCA cycle (*Pdk1*, *Pck1*, *Mdh1*, *Pdhb*, and *Acly*), showed higher expression in the pre-puberty mammary gland. Additionally, 662 genes were downregulated during the transition from pre-puberty to peri-puberty, including those involved in the PPAR signaling pathway (*Pparg*, *Scd*, *Acaca*, *Dgat1*, *Acsl1*, and *Dgat2*), fatty acid metabolism (*Scd*, *Fasn*, *Acaca*, *Acsl1*, *Acsm2*, and *Gpam*), lipid transport and metabolism (*Apoc3*, *Cav1*, *Lep*, *Lpl*, *Apoa1*, and *Fabp4*), and triglyceride biosynthesis (*Dgat1*, *Dgat2*, *Gpam*, and *Cidea*). Those changes in expression are consistent with findings by Fan et al., who used single-cell RNA-seq to identify key genes regulating lipid metabolism (*Zfp36l1*, *Foxo1*, *Lpin1*, *Lpl*, and *Abca1*) in adipocytes across five mammary gland developmental stages¹².

Metabolic regulation is vital during mammary development, as cells require energy and metabolic precursors to proliferate and differentiate. Suburu et al. found that FASN knockout mice exhibited a significant decrease in total fatty acid concentration, particularly in myristic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), stearic acid (C18:0), and linoleic acid (C18:2)²⁶. Similarly, in our study, FASN was downregulated from

pre-puberty to puberty, and a similar decrease was observed in total fatty acid concentration, as well as in those specific fatty acids. Conversely, increasing the expression of PPAR α -regulated genes led to a rise in total fatty acids like C16:0, C16:1, and C18:1 in female Fatp2–/– mice³⁸. PPAR signaling was decreased from pre-puberty to puberty, but only oleic acid levels were affected, suggesting a more complex regulation. However, globally, these findings indicated that there is a significant downregulation of genes involved in lipid synthesis and metabolic processes during the transition from pre-puberty to peri-puberty.

In our lipidomic analysis, we observed a notable decrease in total fatty acid concentration during the transition from pre-puberty to peri-puberty, likely due to the downregulation of lipid metabolism genes such as *Fasn*. The data is consistent with the regulation of *Acaca, Fasn*, and *Scd* expression changes during pregnancy, lactation, and involution periods, correlating with fatty acid contents (C14:1, C18:2, gamma-linolenic acid (C18.3), and arachidonic acid (20:4))³⁹. Additionally, our lipidomic analysis revealed significant differences in 29 out of 43 quantified fatty acids between pre-puberty and peri-puberty. Notably, there was a decrease in saturated fatty acids and omega-6/omega-3 concentrations, which are essential for cell membrane integrity and signaling⁴⁰. Stabilizing lipid profiles from peri-puberty to adulthood suggests a metabolic balance once development is complete. These findings correlate with studies showing that C16:0, C16:1, C18:0, and C18:1 fatty acids become more homogeneous during adipocyte differentiation. However, at the onset of adipogenesis, there is an increase in lauric acid (C12:0) and a decrease in long-chain fatty acids such as behenic acid (C22:0), erucic acid (C22:1), and docosadienoic acid (C22:2)⁴¹. Our findings highlight the dynamic changes in lipid metabolism during mammary gland development, emphasizing the critical role of adipocytes in tissue remodeling and homeostasis. The observed shifts in fatty acid profiles and adipocyte morphology underscore the intricate balance between lipid synthesis, redistribution, and epithelial expansion necessary for proper mammary gland maturation.

The mammary fat pad is home to a complex immune microenvironment, which plays a critical role in tissue development and remodeling. Our analysis identified that cluster 4, representing a specific gene expression pattern, was notably enriched for genes associated with leukocyte activation (*Socs3, Faslg, Tlr9*, and *Cd69*) and cytokines (*Ccl4 and Cxcr5*). In our study, the upregulation of genes involved in lymphocyte activation and adaptive immune responses (*Socs3, Irf7, Traf1, Tnfrsf11a, Sigirr, Tnfaip3, Bcl2l14, Btk, Cd244, Ctla4*, and *Icoslg*) underscores the critical role of immune signaling in mammary tissue remodeling. Previous studies have highlighted the importance of cytokines and genes involved in their signaling, such as IL4, IL13, IL5, and Stat6, produced by Th2 cells, in promoting luminal epithelial cell differentiation and maturation⁴².

Our data also reveal increased expression of genes associated with various immune cells, including T-cells (Cd3e, Tnfrs18, Cd8a, Cd8b, Foxp3), NK cells (Klrd1 [CD94], Klrc1), and B-cells (Cd19, Pax5, Cd79a, Cd79b). It has been demonstrated that the presence of macrophages, derived from circulating monocytes, is crucial in shaping mammary immunity and plays a significant role in the transition from puberty to adulthood⁴³. Factors such as colony-stimulating factor-1 (CSF-1, known as macrophage colony-stimulating factor - M-CSF) and its receptor influence macrophage activity⁴⁴. Lin et al. demonstrated that a lack of macrophages in TEBs leads to altered TEB morphology and poor collagen degradation in CSF-1 null mutant mice^{45,46}. In our analysis, we found an increased expression of genes associated with the presence of macrophages in the transition between pre-puberty to peri-puberty as a (Itgam [CD11B], Fcer2 [CD23], Csf1r)^{7,44}, dendritic cells (Cd74, Tnfrsf14 [HVEM]), and myeloid cells (Cd14, Csf3r)^{15,17}. Similarly, in aged mammary glands, a decrease in myeloid cells coupled with an expansion of lymphoid cells was noted, reflecting age-related immune changes^{44,47}. Key immune cells involved in mammary gland development include macrophages, which assist in matrix reorganization and ductal elongation; mast cells, which are crucial for local immune responses; and eosinophils, which contribute to the remodeling of the ECM^{44,47}. Additionally, deficits in mast cells have been shown to alter TEB numbers at various postnatal weeks, supporting the roles of mast cells in mammary tissue restructuring, maintenance, and repair⁴⁷⁻⁴⁹. The significant enrichment of immune response genes during the transition from pre-puberty to peri-puberty highlights the essential role of immune signaling in mammary gland remodeling and development. The complex interplay between cytokines, immune cells, and regulatory genes underscores the intricate balance of immune processes necessary for effective mammary tissue maturation and development during critical transitional periods.

In conclusion, this study provides a comprehensive view of the morphological, transcriptional, and metabolic changes in the mammary gland during pre-puberty, peri-puberty, and adulthood. The results highlight the complexity of mammary development and underscore the importance of metabolic and proliferative regulation, cellular signaling, and immune response in these processes. The integration of morphological, transcriptional, and lipidomic analyses offers a robust platform for future research to understand the underlying mechanisms of mammary development, which may also have implications for studying diseases related to the mammary gland, such as breast cancer.

Materials and methods

Animals

All experiments involving rats were performed following the guidelines set out by the Canadian Council of Animal Care (CCAC) and the ARRIVE guideline. This research was approved by the Institutional Animal Care and Use Committee of the INRS (Protocols 2202-02). Nulliparous female Sprague-Dawley rats were kindly donated by Geraldine Delbès⁵⁰. Rats were weighed and euthanized by CO_2 followed by cervical dislocation at different time points: pre-puberty (PND21), peri-puberty (PND46), and adulthood (PND90). For each time point, between 5 and 7 animals were sacrificed, and two pairs of mammary glands (thoracic and inguinal) were taken and weighed.

Whole-mount staining and analysis

Sample preparation

The right inguinal mammary gland was processed as described previously^{51,52}. Briefly, it was dissected, placed on glass slides, and fixed in Carnoy's solution (6:3:1 of 100% ethanol, chloroform, and glacial acetic acid) overnight at room temperature (RT). Samples were rehydrated again through serial ethanol gradient from 70 to 0% in water and stained in carmine alum (2% carmine, 5% potassium aluminum sulfate in water) overnight at RT. Samples were dehydrated through serial ethanol baths and cleared in xylene. Finally, samples were mounted with Permount (FisherChemical, Ontario, Canada, no. SP15-500). Images were captured using a Canon PowerShot G9x digital camera on a transilluminator (Henning Graphics LR299343), and a measurement scale was used to compare sample sizes.

Epithelial area and branching complexity measurement

The epithelial area analysis was quantified for all animals (n=5-7) using whole-mount. The scale was set for all images, and the area was measured in cm² and analyzed using the skeletonize tool of ImageJ software (http s://imagej.net/Fiji/Downloads). The skeletonized image was used for the branching complexity, and between 3 and 5 representative sections were taken. The number of intersections (N) per cm² was analyzed using the Sholl analysis plugin from ImageJ^{53,54}.

RNA extraction

Four randomly chosen samples per group were used to extract the RNA using the Aurum total RNA fatty and fibrous tissue kit (Bio-Rad, Ontario, Canada, no. 7326830) according to the manufacturer's instructions (between 50 and 100 mg of the left inguinal mammary gland for each animal). RNA integrity number (RIN) was verified using the Agilent 2100 Bioanalyzer instrument and the Agilent RNA 6000 Nano Kit; all samples showed RIN > 8 and could thus be used for sequencing analysis. RNA concentration and purity were measured using a Nanodrop spectrophotometer (Thermo Scientific). Extracted RNA samples were sent for RNA sequencing to the Genomic Centre of the Centre de recherche du CHU de Québec – Université Laval for RNA-seq analysis using a HiSeq 2500 (125 bp paired-end sequencing), as previously described⁵⁵.

Sequencing data analyses

The raw sequencing data quality was checked using FastQC v0.12.0 before being trimmed using TrimGalore v0.6.10. The quality was then reverified with FastQC and aggregated with MultiQC v1.2. The trimmed RNA sequences with high-quality reads were aligned to the Rattus norvegicus Rnor_6.0 reference transcriptome (ht tps://may2021.archive.ensembl.org/Rattus_norvegicus) using Kallisto v0.46.1 pseudo-aligner, sequencing data were deposited in NCBI under the accession number PRJNA1157723.

The differential gene expression analysis was performed using the R-Package DESeq2 v1.42.1. To determine each group's molecular signatures and the average gene expression, k-means for gene clustering algorithms were used. To determine differentially expressed genes, a threshold of Benjamini-Hochberg false discovery rates (FDR) p-adj < 0.05 and absolute \log_2 FC (fold change) 1.5 was used. To study the biological pathways regulated in the transition between developmental groups, Gene Set Enrichment Analysis (GSEA) was used. Gene analyses were conducted using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment tools^{20–22}, facilitated by the SRplot package (http://www.bioinformatics.com.cn) and R software environment. To identify biological pathways enriched in gene clusters and visualize the similarities of enriched terms, we used Metascape (https://metascape.org/) and Enrichr (https://maayanlab.cloud/Enrichr/).

Gene expression analysis by RT-qPCR

After purification, RNA was used to synthesized cDNA. To this end, the reverse transcription reaction was performed using the iScript cDNA synthesis kit (Biorad, no. 1708891, CA, USA) following the manufacturer's protocol. Then, qPCR analyses were performed on a CFX96 Touch Real-Time PCR Detection System. Oligonucleotide primers (*Cd3e, Traf1, Irf7,* and *Tnfrsf11a*) were designed using Primer Blast (https://www.n cbi.nlm.nih.gov/tools/primer-blast/; last accessed Jan 13, 2025), and *Scd, Fabp4, Ppary, Actb, Rpl13a, G6pd, Gapdh, Eef1a1,* and *Hprt* primers were validated in a previous study⁵². qPCR assays were performed with the SsoAdvanced SYBR green Supermix (Biorad, no. 1725274), and results were analyzed using the CFX Maestro Sofware (Biorad). The efficiency and the specificity of each qPCR reaction were done for each pair of primers by the standard curve and dissociation curves analysis of the PCR products, respectively^{56,57}. We used 6 reference genes, and *Actb, Rpl13a, and Eef1a1* were selected based on their stability throughout the developmental stages using the geNorm algorithm⁵⁸. Amplification curves were next analyzed using the comparative cycle threshold method ($\Delta\Delta$ Ct method).

Cryosection and Masson's trichrome analysis

For each animal, the right thoracic mammary glands were dissected and immediately embedded in cyromatrix (OCT Cryomatrix, Fisher Scientific, Cat. 23-730-571) on dry ice and stored at -80°C. Frozen tissues were cut using a cryostat into 5 μ m sections, fixed in 10% formalin overnight at RT, and stained using Masson Trichrome. Briefly, sections were immersed in Weigert's iron hematoxylin for 10 min, Biebrich scarlet-acid fuchsin for 15 min, phosphomolybdic-phosphotungstic acid for 20 min, and aniline blue for 5 min, washing with water after each step. Finally, the samples were immersed in 1% acetic acid for 5 min. The sections were then dehydrated by immersion in 95% and 100% ethanol for 5 min each and cleared in xylene for 5 min. Samples were mounted using coverslips and Permount. Images were captured using a confocal microscope Nikon A1R + equipped with a digital camera (Nikon) and analyzed using ImageJ. The area of the adipocyte with an intact structure was

measured using the drawing tool; for each image, the complete adipose tissue was measured, and the number of adipocytes and area was determined using the plugins from ImageJ called Adiposoft⁵⁹.

Lipids quantification

A lipidomic profile was performed from snap-frozen thoracic mammary glands. After being crushed in liquid nitrogen on dry ice and weighted, the samples were homogenized in saline 9%. Then, homogenates were spiked with the internal standard phosphatidylcholine C21:0 (Sigma Aldrich), and the lipids were extracted with chloroform\methanol solution (2:1 v/v) according to a modified Folch method⁶⁰. After centrifugation, the lipid phases were collected and dried under a nitrogen flow. All the samples were resuspended in 2 ml of methanol/ benzene (4:1 v/v) and methylated with acetyl chloride⁶¹. The fatty acids profile was realized by capillary gas chromatography using a temperature gradient on an HP5890 gas chromatograph (Hewlett Packard, Toronto, Canada) equipped with an HP-88 capillary column (100 m x 0.25 mm i.d. x 0.20 μ m film thickness; Agilent Technologies) coupled with a flame ionization detector (FID). Helium was used as carrier gas (split ratio 1:50).

Fatty acids were identified according to their retention time, using the following standard mixtures as a basis for absolute quantification: the FAME 37 mix (Supelco Inc., Bellefonte, PA), the GLC-411 fatty acid mix (NuChek Prep Inc, Elysian, MN), the methylated fatty acids C22:5 w6 (Larodan AB, Malmö, Sweden), the methylated fatty acids C22:5 w3 (Supelco Inc., Bellefonte, PA), a mixture of trans-FA containing: C18:2 w6 cis/trans (Supelco Inc Bellefonte, PA), a mixture of cis/trans C18:3 w3 (Supelco Inc Bellefonte, PA), and the following Nucheck fatty acids: C14:1 trans-9, C16:1 trans-9, and finally isoforms of C18:1 (cis-6, trans-6, cis-11, trans-11: Nucheck, and cis-12, cis-13: Supelco Inc.). Results were expressed as percent of total fatty acids and mgFA/g of mammary gland tissues.

Bioinformatic and statistical analysis

All the statistical analyses were done using GraphPad Prism 9 and the R-Studio environment. Descriptive analysis of the data, such as mean, median, and standard deviation, was performed. The normality of the distribution was verified using Shapiro-Wills or Kolmogorov-Smirnov normality test. Data that satisfied assumptions of normality and homoscedasticity were analyzed using Anova and student's t-test. Otherwise, Kruskal-Wallis and Mann-Whitney U-test non-parametric tests were used. Pearson's correlation was used to measure the degree of relationship between variables. For the differential gene expression, p-adj < 0.05, and changes of Log_2 fold of 1.5 were considered significant. For other analyses, p-value < 0.05 was considered as a significant difference.

Visualization techniques such as volcano plots, complex heatmaps, principal component analysis (PCA), boxplots, bar plots, and Dot plots were performed using an R environment. Venn diagrams were generated with the jvenn tool (available; https://jvenn.toulouse.inrae.fr/app/index.html).

Data availability

The authors confirm that the data supporting the findings of this study are available within the article and its Supplementary materials. Raw data that support the findings have been deposited in Sequenced Read Archive (SRA) under accession number PRJNA1157723. https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA1157723.

Received: 13 September 2024; Accepted: 4 April 2025 Published online: 10 April 2025

References

- 1. Musumeci, G. et al. Mammary gland: From embryogenesis to adult life. *Acta Histochem.* 117, 379–385. https://doi.org/10.1016/j.a cthis.2015.02.013 (2015).
- Biswas, S. K., Banerjee, S., Baker, G. W., Kuo, C. Y. & Chowdhury, I. The mammary gland: Basic structure and molecular signaling during development. Int. J. Mol. Sci. 23, 3883 (2022).
- 3. Hitchcock, J., Hughes, K., Harris, O. & Watson, C. Dynamic architectural interplay between leucocytes and mammary epithelial cells. *FEBS J.* 287, 250–266 (2020).
- Inman, J. L., Robertson, C., Mott, J. D. & Bissell, M. J. Mammary gland development: Cell fate specification, stem cells and the microenvironment. *Development* 142, 1028–1042. https://doi.org/10.1242/dev.087643 (2015).
- Dziegelewska-Sokolowska, Z., Majewska, A., Prostek, A. & Gajewska, M. Adipocyte-Derived paracrine factors regulate the in vitro development of bovine mammary epithelial cells. *Int. J. Mol. Sci.* 24 https://doi.org/10.3390/ijms241713348 (2023).
- Li, S. et al. Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. J. Histochem. Cytochem. 58, 509–515. https://doi.org/10.1369/jhc.2009.954644 (2010).
- Henry, S. et al. Characterization of gene expression signatures for the identification of cellular heterogeneity in the developing mammary gland. J. Mammary Gland Biol. Neoplasia. 26, 43–66. https://doi.org/10.1007/s10911-021-09486-3 (2021).
- Colleluori, G., Perugini, J., Barbatelli, G. & Cinti, S. Mammary gland adipocytes in lactation cycle, obesity and breast cancer. *Rev. Endocr. Metab. Disord.* 22, 241–255. https://doi.org/10.1007/s11154-021-09633-5 (2021).
- Wang, Q. A. et al. Reversible De-differentiation of Mature White Adipocytes into Preadipocyte-like Precursors during Lactation. Cell Metab. 28, 282–288 e283 (2018). https://doi.org/10.1016/j.cmet.2018.05.022
- 10. Hovey, R. C. & Aimo, L. Diverse and active roles for adipocytes during mammary gland growth and function. J. Mammary Gland Biol. Neoplasia 15, 279–290 (2010).
- Ganeshalingam, M. et al. Role of lipidomics in assessing the functional lipid composition in breast milk. Front. Nutr. 9, 899401. https://doi.org/10.3389/fnut.2022.899401 (2022).
- Fan, Y. et al. A cell transcriptomic profile provides insights into adipocytes of Porcine mammary gland across development. J. Anim. Sci. Biotechnol. 14, 126. https://doi.org/10.1186/s40104-023-00926-0 (2023).
- Geiger, A. J. & Hovey, R. C. Development of the mammary glands and its regulation: How not all species are equal. Anim. Front. 13, 51-61. https://doi.org/10.1093/af/vfad029 (2023).
- Dos Santos, C. O. et al. Molecular hierarchy of mammary differentiation yields refined markers of mammary stem cells. Proc. Natl. Acad. Sci. USA 110, 7123–7130. https://doi.org/10.1073/pnas.1303919110 (2013).
- 15. Bach, K. et al. Differentiation dynamics of mammary epithelial cells revealed by single-cell RNA sequencing. *Nat. Commun.* **8**, 2128. https://doi.org/10.1038/s41467-017-02001-5 (2017).

- Wu, S. Z. et al. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. EMBO J. 39, e104063. https://doi.org/10.15252/embj.2019104063 (2020).
- Pal, B. et al. Construction of developmental lineage relationships in the mouse mammary gland by single-cell RNA profiling. *Nat. Commun.* 8, 1627. https://doi.org/10.1038/s41467-017-01560-x (2017).
- Li, C. M. et al. Aging-Associated alterations in mammary epithelia and stroma revealed by single-cell RNA sequencing. *Cell. Rep.* 33, 108566. https://doi.org/10.1016/j.celrep.2020.108566 (2020).
- Doria, M. L. et al. Fatty acid and phospholipid biosynthetic pathways are regulated throughout mammary epithelial cell differentiation and correlate to breast cancer survival. FASEB J. 28, 4247–4264. https://doi.org/10.1096/fj.14-249672 (2014).
- Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. *Nucleic Acids Res.* 53, D672–D677 (2025).
- 21. Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951 (2019).
- 22. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 28, 27–30 (2000).
- Aguilar-Recarte, D. et al. GDF15 mediates the metabolic effects of PPARbeta/delta by activating AMPK. Cell. Rep. 36, 109501. https://doi.org/10.1016/j.celrep.2021.109501 (2021).
- Avagliano, A. et al. Influence of fibroblasts on mammary gland development, breast cancer microenvironment remodeling, and cancer cell dissemination. *Cancers (Basel)*. 12. https://doi.org/10.3390/cancers12061697 (2020).
- Zhu, J. & Thompson, C. B. Metabolic regulation of cell growth and proliferation. Nat. Rev. Mol. Cell. Biol. 20, 436–450. https://doi .org/10.1038/s41580-019-0123-5 (2019).
- Suburu, J. et al. Fatty acid synthase is required for mammary gland development and milk production during lactation. Am. J. Physiol. Endocrinol. Metab. 306, E1132–1143. https://doi.org/10.1152/ajpendo.00514.2013 (2014).
- Furstova, V., Kopska, T., James, R. F. & Kovar, J. Comparison of the effect of individual saturated and unsaturated fatty acids on cell growth and death induction in the human pancreatic beta-cell line NES2Y. *Life Sci.* 82, 684–691. https://doi.org/10.1016/j.lfs.2007 .12.023 (2008).
- Reiss, K., Cornelsen, I., Husmann, M., Gimpl, G. & Bhakdi, S. Unsaturated fatty acids drive disintegrin and metalloproteinase (ADAM)-dependent cell adhesion, proliferation, and migration by modulating membrane fluidity. *J. Biol. Chem.* 286, 26931–26942. https://doi.org/10.1074/jbc.M111.243485 (2011).
- 29. Samovski, D. & Jacome-Sosa, M. Fatty acid transport and signaling: Mechanisms and physiological implications. Annu. Rev. Physiol. 85, 317–337. https://doi.org/10.1146/annurev-physiol-032122-030352 (2023).
- Augimeri, G. et al. A conjugate of dopamine and eicosapentaenoic acid (EPA), exerts Anti-inflammatory properties in mouse and human macrophages. *Nutrients* 11, 2247. https://doi.org/10.3390/nu11092247 (2019). N-Eicosapentaenoyl Dopamine.
- Nerger, B. A. & Nelson, C. M. 3D culture models for studying branching morphogenesis in the mammary gland and mammalian lung. *Biomaterials* 198, 135–145. https://doi.org/10.1016/j.biomaterials.2018.08.043 (2019).
- 32. Hassiotou, F. & Geddes, D. Anatomy of the human mammary gland: Current status of knowledge. *Clin. Anat.* 26, 29–48. https://d oi.org/10.1002/ca.22165 (2013).
- Peters, A., Ingman, W., Tilley, W. D. & Butler, L. Differential effects of exogenous androgen and an androgen receptor antagonist in the peri-and postpubertal murine mammary gland. *Endocrinology* 152, 3728–3737 (2011).
- Martin, F., Stein, T. & Howlin, J. Mammary gland development. Wiley Interdisciplinary Reviews: Dev. Biology. 1501, 358. https://d oi.org/10.1007/978-1-4939-6475-8 (2017).
- Hannan, F. M., Elajnaf, T., Vandenberg, L. N., Kennedy, S. H. & Thakker, R. V. Hormonal regulation of mammary gland development and lactation. *Nat. Rev. Endocrinol.* 19, 46–61. https://doi.org/10.1038/s41574-022-00742-y (2023).
- Kleinberg, D. L., Ruan, W. & IGF-I GH, and sex steroid effects in normal mammary gland development. J. Mammary Gland Biol. Neoplasia. 13, 353–360. https://doi.org/10.1007/s10911-008-9103-7 (2008).
- Heckman, B. M. et al. Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development. *Dev. Biol.* 309, 137–149. https://doi.org/10.1016/j.ydbio.2007.07.002 (2007).
- Perez, V. M. et al. Deletion of fatty acid transport protein 2 (FATP2) in the mouse liver changes the metabolic landscape by increasing the expression of PPARalpha-regulated genes. J. Biol. Chem. 295, 5737–5750. https://doi.org/10.1074/jbc.RA120.012730 (2020).
- Kęsek-Woźniak, M. et al. ACACA, FASN and SCD gene expression in somatic cells throughout lactation and its relation to fatty acid profile in cow milk. Anim. Sci. Pap Rep. 41, 17–26 (2023).
- Mukerjee, S., Saeedan, A. S., Ansari, M. N. & Singh, M. Polyunsaturated fatty acids mediated regulation of membrane biochemistry and tumor cell membrane integrity. *Membr. (Basel)* 11. https://doi.org/10.3390/membranes11070479 (2021).
- Miehle, F. et al. Lipidomic phenotyping reveals extensive lipid remodeling during adipogenesis in human adipocytes. *Metabolites* 10 https://doi.org/10.3390/metabo10060217 (2020).
- Khaled, W. T. et al. The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development. *Development* 134, 2739–2750. https://doi.org/10.1242/dev.003194 (2007).
- 43. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958–969 (2008).
- Beaudry, K. L., Parsons, C. L., Ellis, S. E. & Akers, R. M. Localization and quantitation of macrophages, mast cells, and eosinophils in the developing bovine mammary gland. J. Dairy. Sci. 99, 796–804. https://doi.org/10.3168/jds.2015-9972 (2016).
- Sternlicht, M. D. Key stages in mammary gland development: The cues that regulate ductal branching morphogenesis. Breast Cancer Res. 8, 1–11 (2005).
- Lin, E. Y., Gouon-Evans, V., Nguyen, A. V. & Pollard, J. W. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia 7, 147–162. https://doi.org/10.1023/a:1020399802795 (2002).
- Need, E. F., Atashgaran, V., Ingman, W. V. & Dasari, P. Hormonal regulation of the immune microenvironment in the mammary gland. J. Mammary Gland Biol. Neoplasia 19, 229–239. https://doi.org/10.1007/s10911-014-9324-x (2014).
- Lilla, J. N. & Werb, Z. Mast cells contribute to the stromal microenvironment in mammary gland branching morphogenesis. *Dev. Biol.* 337, 124–133. https://doi.org/10.1016/j.ydbio.2009.10.021 (2010).
- Aupperlee, M. D. et al. Epidermal growth factor receptor (EGFR) signaling is a key mediator of Hormone-Induced leukocyte infiltration in the pubertal female mammary gland. *Endocrinology* 155, 2301–2313. https://doi.org/10.1210/en.2013-1933 (2014).
- Lecante, L. L., Gaye, B. & Delbes, G. Impact of in utero rat exposure to 17Alpha-Ethinylestradiol or genistein on testicular development and germ cell gene expression. Front. Toxicol. 4, 893050. https://doi.org/10.3389/ftox.2022.893050 (2022).
- 51. Gouesse, R. J. et al. Gestational and lactational exposure to an environmentally relevant mixture of brominated flame retardants downregulates junctional proteins, thyroid hormone receptor alpha1 expression, and the Proliferation-Apoptosis balance in mammary glands post puberty. *Toxicol. Sci.* **171**, 13–31. https://doi.org/10.1093/toxsci/kfz147 (2019).
- 52. Crobeddu, B. et al. Gestational and lactational exposure to the emergent alternative plasticizer 1,2-Cyclohexane Dicarboxylic acid diisononyl ester (DINCH) impairs lipid metabolism to a greater extent than the commonly used Di(2-Ethylhexyl) phthalate (DEHP) in the adult rat mammary gland. *Toxicol. Sci.* 189, 268–286. https://doi.org/10.1093/toxsci/kfac076 (2022).
- Stanko, J. P., Easterling, M. R. & Fenton, S. E. Application of Sholl analysis to quantify changes in growth and development in rat mammary gland whole mounts. *Reprod. Toxicol.* 54, 129–135. https://doi.org/10.1016/j.reprotox.2014.11.004 (2015).
- Stanko, J. P. & Fenton, S. E. Quantifying branching density in rat mammary gland Whole-mounts using the Sholl analysis method. J. Vis. Exp. 124, e55789. https://doi.org/10.3791/55789 (2017).
- Germain, L. et al. Alternative splicing regulation by the androgen receptor in prostate cancer cells. J. Steroid Biochem. Mol. Biol. 202, 105710. https://doi.org/10.1016/j.jsbmb.2020.105710 (2020).

- Taylor, S. C. et al. The ultimate qPCR experiment: Producing publication quality, reproducible data the first time. *Trends Biotechnol.* 37, 761–774. https://doi.org/10.1016/j.tibtech.2018.12.002 (2019).
- Taylor, S. C. & Mrkusich, E. M. The state of RT-quantitative PCR: Firsthand observations of implementation of minimum information for the publication of quantitative real-time PCR experiments (MIQE). J. Mol. Microbiol. Biotechnol. 24, 46–52. https://doi.org/10.1159/000356189 (2014).
- Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 3, RESEARCH0034. https://doi.org/10.1186/gb-2002-3-7-research0034 (2002).
- Galarraga, M. et al. Adiposoft: Automated software for the analysis of white adipose tissue cellularity in histological sections. J. Lipid Res. 53, 2791–2796. https://doi.org/10.1194/jlr.D023788 (2012).
- Shaikh, N. A. & Downar, E. Time course of changes in Porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. *Circ. Res.* 49, 316–325. https://doi.org/10.1161/01.res.49.2.316 (1981).
- 61. Lepage, G. & Roy, C. C. Direct transesterification of all classes of lipids in a one-step reaction. J. Lipid Res. 27, 114-120 (1986).

Acknowledgements

The authors are thankful to Fabien Joao and Rhizlane ElOmri for their technical support.

Author contributions

D.T.P., Conceptualization, methodology, software, formal analysis, investigation, resources, data curation, writing - original draft, writing - review & editing, and visualization. A.M., Conceptualization, methodology, investigation. M.J., Conceptualization and methodology. J.C., Conceptualization and methodology. M.S.S., software and formal analysis. L.B., Methodology. G.D. Conceptualization and methodology. M.P., Conceptualization, methodology, investigation, supervision, project administration, and funding acquisition. E.A.W., Conceptualization, methodology, investigation, supervision, project administration, and funding acquisition. I.P., Conceptualization, methodology, investigation, supervision, project administration, and funding acquisition.

Funding

This work was supported by funding to IP, MP, and EAW from the National Sciences and Engineering Research Council of Canada (NSERC; RGPIN-2020-05726, RGPIN-2023-0523 and RGPIN-2019-04740, respectively). DT is supported by scholarships from the Réseau Québecois en reproduction and Fondation Armand-Frappier.

Declarations

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/1 0.1038/s41598-025-97532-z.

Correspondence and requests for materials should be addressed to I.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

© The Author(s) 2025